AU2012202645A1 - Variants of Hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof - Google Patents

Abstract

C\NRPonbThDCCAAR\43063_IDOC-/93 5/202 The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (-IBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HIBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

Description

Pi// i0i Regulation 3 2 A U STR A L I A Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT (ORIGINAL) Name of Applicant: Melbourne Health of Level 6-6 East Royal Melbourne Hospital, Grattan Street, Parkville, Victoria 3050, Australia AND St. Vincent's Hospital (Melbourne) Ltd trading as St. Vincent's Hospital Melbourne of 41 Victoria Parade, Fitzroy, Victoria 3065, Australia AND Austin Health of Studley Road, Heidelberg, Victoria 3084, Australia Actual Inventors: Angeline Ingrid BARTHOLOMEUSZ, Stephen LOCARNINI, Anna AYRES, Margaret LITTLEJOHN, Paul DESMOND, Peter William ANGUS Address for Service: DAVIES COLLISON CAVE, Patent & Trademark Attorneys, of l Nicholson Street, Melbourne, 3000, Victoria, Australia Ph: 03 9254 2777 Fax: 03 9254 2770 Attorney Code: DM Invention Title: Variants of Hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof The following statement is a full description of this invention, including the best method of performing it known to us:- C.\NRPortblDCC\AAR\41f1691 DOC.-4/052012 - 1 VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF This application is a divisional of Australian Application No. 2006230802, the entire 5 contents of which are incorporated herein by reference. BACKGROUND OF THE INVENTION FIELD OF THE INVENTION 10 The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (-BV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced 15 interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular -IBV variants. The present invention also contemplates the use of the viral variants to screen for 20 and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus. DESCRIPTION OF THE PRIOR ART 25 Bibliographic details of the publications referred to in this specification are also collected at the end of the description. The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common 30 general knowledge in any country.

-2 Hepatitis B virus (HBV) can cause debilitating disease conditions and can lead to acute liver failure. HBV is a DNA virus which replicates via an RNA intermediate and utilizes reverse transcription in its replication strategy (Summers and Mason, Cell 29: 403-415, 1982). The HBV genome is of a complex nature having a partially double-stranded DNA 5 structure with overlapping open reading frames encoding surface, core, polymerase and X genes. The complex nature of the H1BV genome is represented in Figure 1. The polymerase consists of four functional regions, the terminal protein (TP), spacer, reverse transcriptase (rt) and ribonuclease (RNAse). 10 The polymerase gene of HBV overlaps the envelope gene, mutations in the catalytic domain of the polymerase gene can also affect the nucleotide and the deduced amino acid sequence of the envelope protein and vice versa. In particular, the genetic sequence for the neutralization domain of HBV known as the 'a' determinant, which is found within the HBsAg and located between amino acids 99 and 169, actually overlaps the major catalytic 15 regions of the viral polymerase protein and in particular domains A and B. The presence of an HBV DNA polymerase has led to the proposition that nucleoside or nucleotide analogs could act as effective anti-viral agents. Examples of nucleoside or nucleotide analogs currently being tested are penciclovir and its oral form (FCV) [Vere 20 Hodge, Antiviral Chem Chemother 4: 67-84, 1993; Boyd ei al., Antiviral Chem Chemother. 32: 358-363, 1987; Kruger el al., Hepatology 22: 219A, 1994; Main el al., J. Viral 1Hepatitis 3: 211-215, 1996], Lamivudine [(-)-$-2'-deoxy-3'-thiacytidine]; (3TC or LMV) [Severini et al., Antimicrobial Agents Chemoiher. 39: 430-435, 1995; Dienstag el al., New England J Med 333: 1657-1661, 19951. New nucleoside or nucleotide analogs 25 which have already progressed to clinical trials include the pyrimidines Emtricitabine, ((-) p--L-2'-3'-dideoxy-5-fluoro-3'-thiacydidine; FTC), the 5-fluoro derivative of 3TC. and Clevudine (1-(2-fluoro-5-methyl-p-L-arabino-furanosyl) uracil; L-FMAU), a thymidine analog. Like 3TC, these are pyrimidine derivatives with an unnatural "L"- configuration. Several purine derivatives have also progressed to clinical trials; they include Entecavir 30 (BMS-200, 475; ETV), a carbocyclic deoxyguanosine analog, diaminopurine dioxolane (DAPD), an oral pro-drug for dioxolane guanine ((-)-p-D-2-aminopurine dioxolane; DXG) C:\NRPonbl\DCC\AAR\4MW1_I DOC4/0/2'I12 -3 and Adefovir dipivoxil, an oral prodrug for the acyclic deoxyadenosine monophosphate nucleoside or nucleotide analog Adefovir (9-[phosphonyl-methoxyethyl]-adenine; PMEA). Other drugs in pre-clinical and clinical trials include FLG [Medivir], ACH-126,443 (L d4C) [Archillion Pharmaceuticals], ICN 2001-3 (ICN) and Racivir (RCV) [Pharmassett]. 5 Whilst these agents are highly effective in inhibiting HBV DNA synthesis, there is the potential for resistant mutants of -IBV to emerge during long term antiviral chemotherapy. In patients on prolonged LMV therapy, key resistance mutations are selected in the rt domain within the polymerase at rtM2041/V +/- rtL180M as well as other mutations. The 10 nomenclature used for the polymerase mutations is in accordance with that proposed by Stuyver et al., 2001, supra. LMV is a nucleoside or anucleotide analog that has been approved for use against chronic HBV infection. LMV is a particularly potent inhibitor of HBV replication and reduces HIBV DNA titres in the sera of chronically infected patients after orthotopic liver transplantation (OLT) by inhibiting viral DNA synthesis. LMV 15 monotherapy seems unlikely to be able to control -IBV replication in the longer term. This is because emergence of LMV-resistant strains of -IBV seems almost inevitable during monotherapy. Adefovir dipivoxil (ADV: formerly, bis-pom PMEA) is an orally available prodrug of the 20 acyclic deoxyadenosine monophosphate analog adefovir (formerly, PMEA) (Figure 2). ADV is also a potent inhibitor of -lBV replication and has recently been given FDA approval for use against chronic -IBV infection. Adefovir dipivoxil differs from other agents in this class in that it is a nucleotide (vs. nucleoside) analog and as such bypasses the first phosphorylation reaction during drug activation. This step is often rate-limiting. 25 Adefovir dipivoxil has demonstrated clinical activity against both wild-type and lamivudine-resistant strains of HBV and is currently in phase III clinical Testing (Gilson et al., J Viral Hepat 6: 387-395, 1999; Perrillo et al., Hepatology 32: 129-134, 2000; Peters et al., Transplantal ion 68: 1912-1914, 1999; Benhamou el al., Lancet 358: 718-723, 2001). During phase Il studies a 30 mg daily dose of adefovir dipivoxil resulted in a mean 30 4 logo decrease in viremia over 12 weeks (lIeathcote el al., Hepatology 28: A620, 1998).

C:NRPortbl\CCAARW3'691_t DOC-l.S0/20I2 -4 ADV is a substituted acyclic nucleoside phosphonate. This class of compounds also includes tenofovir disoproxil fumarate (also referred to as tenofovir DF, or tenofovir, or (TFV) or 9-R-(2-phosphonomethoxypropyl)adenine (PMPA) and is marketed as Viread by Gilead sciences). 5 TFV has antiviral activity against both HBV and HIIV (Ying et al., J Viral Hepal. 7(2). 161-165, 2000; Ying el al., J. Viral Hepat. 7(1): 79-83, 2000, 2000; Suo el al., J Biol Chem. 273(42): 27250-27258. 1998). 10 FTC has activity against HBV and HIV (Frick et al., Antimicrob Agents Chemother 37: 2285-2292, 1993). Nucleoside or nucleotide analog therapy may be administered as monotherapy or combination therapy where two or more nucleoside or nucleotide analogs may be 15 administered. The nucleoside or nucleotide analogs may also be administered in combination with other antiviral agents such as interferon or hepatitis B immunoglobulin (-1 BIG). There is a need to monitor for the emergence of nucleoside/nucleotide-analog- or antibody 20 resistant strains of HBV and to develop diagnostic protocols to detect these resistant viruses and/or to use them to screen for and/or develop or design agents having properties making them useful as anti-viral agents. Defective forms of these resistant strains or antigenic components therefrom are also proposed to be useful in the development of therapeutic vaccine compositions as are antibodies directed to viral surface components.

C\NRPonbI1DCC\AAH\.fl4W3_1 DOC-4/"5/2012 -5 SUMMARY OF THE INVENTION Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the 5 inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers. Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO:). The SEQ ID NOs: correspond numerically to the sequence identifiers <400>1 10 (SEQ ID NO:1), <400>2 (SEQ ID NO:2), etc. A summary of the sequence identifiers is provided in Table 1. A sequence listing is provided after the claims. Specific mutations in an amino acid sequence are represented herein as "XaajnXaa 2 " where Xaai is the original amino acid residue before mutation, n is the residue number and 15 Xaa 2 is the mutant amino acid. The abbreviation "Xaa" may be the three letter or single letter (i.e. "X") code. An "rt" before "XaainXaa 2 " means "reverse transcriptase". An "s" means an envelope gene. The amino acid residues for HBV DNA polymerase are numbered with the residue methionine in the motif Tyr Met Asp Asp (YMDD) being residue number 204 (Stuyver et al., Hepatology 33: 751-757, 2001). The amino acid 20 residues for hepatitis B virus surface antigen are number according to Norder et al. (J. Gen. Virol. 74: 341-1348, 1993). Both single and three letter abbreviations are used to define amino acid residues and these are summarized in Table 2. In accordance with the present invention, the selection of HBV variants is identified in 25 patients with chronic HBV infection treated with ADV and/or LMV. Consequently, -IBV rt variants are contemplated which are resistant to, or which exhibit reduced sensitivity to, ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV: FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and LMV; IV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and 30 LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and C \NRPonbhDCCAAR\4W,9l_ I DOC-4/1V21112 -6 ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. 5 Corresponding mutations in the surface antigen also occur. The identification of these lBV variants is important for the development of assays to monitor ADV, LMV, FTC and/or TFV resistance and/or resistance with ETV in combination with any nucleoside or nucleotide analog with the exception of LMV and/or resistance to other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof and to screen for 10 agents which are useful as alternative therapeutic agents. The subject variants are not proposed to exhibit resistance to ETV alone or ETV and LMV alone. Reference herein to "anti--IBV agents" includes nucleoside and nucleotide analogs as well as immunological reagents (e.g. antibodies to HBV surface components) and chemical, 15 proteinaceous and nucleic acid agents which inhibit or otherwise interfere with viral replication, maintenance, infection, assembly or release. The detection of such HBV variants is particularly important in the management of therapeutic protocols including the selection of appropriate agents for treating HBV 20 infection. The method of this aspect of the present invention is predicated in part on monitoring the development in a subject of an increased H3V load in the presence of a nucleoside or nucleotide analog or other anti-HBV agents or combinations thereof. The clinician is then able to modify an existing treatment protocol or select an appropriate treatment protocol accordingly. 25 Accordingly, one aspect of the present invention is directed to an isolated Hepatitis B virus (HBV) variant wherein said variant comprises a nucleotide mutation in a gene encoding a DNA polymerase resulting in at least one amino acid addition, substitution and/or deletion to said DNA polymerase and wherein said variant exhibits decreased sensitivity to one or 30 more nucleoside or nucleotide analogs selected from the list consisting of ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and C:NRPonbl)CC\AAR\U4)'V91_ DOC-15/212 -7 TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and 5 TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti--IBV agents or combinations thereof. With the proviso that the HBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. The variant HBV comprises a mutation in an overlapping open reading frame in its genome in a region 10 defined by one or more of domains F and G and domain A through to E of IBV DNA polymerase. Another aspect of the present invention provides an isolated HBV variant comprising a nucleotide mutation in the S gene resulting in at least one amino acid addition, substitution 15 and/or deletion to the surface antigen and which exhibits decreased sensitivity to one or more nucleoside or nucleotide analogs selected from the list consisting of ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV;ETV and FTC; E'TV and FV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, 20 ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. With the proviso that the H1BV variant 25 does not exhibit resistance to ETV alone or ETV or LMV alone. Useful mutants in the rt region include, in one embodiment, mutations at codons rtN53, rtY54, rtLl80, rtTl8l, rtTl84, rtM204, rtN236, rtYl24, rtH126, rtTl28, rtSl35, rtLl80, rtS202, rtM204, rtH248, rt153, rtS54, rtNl22, rtM145, rtLl80, rtM204, rtM250, rtN53, 30 rtS85, rtSll6, rtDl34, rtNl39, rtQl49, rtAl8l, rtS219, rt1233, rtN236 or rtM250. Particular mutants include rtN53, rtN53, rtY54, rtLl80, rt1181, rtTl84, rtM204, and C\NRPonbIDCC\AAR\31691I _DOC-4/5/2012 -8 rtN236, in another embodiment include rtYl24, rtH126, rtTl28, rtSl35, rtLI80, rtS202, rtM204, and rtl-1248, or yet another embodiment include rtl53, rtS54, rtNl22, rtMl45, rtL180, rtM204 and rtM250, or yet another embodiment rtN53, rtS85, rtSl16, rtD134, rtN139, rtQl49, rtA181, rtS219, rt1233, rtN236, rtM250 or a combination thereof or an 5 equivalent mutation. Even more particular mutants include rtN53K, rtN53K/N, rtY54D, rtLl80M, rtTl8lA/V, rtTl84S, rtM204V, and rtN236T, in another embodiment include rtYl24H, rtH126R, rtT128N, rtSl35C, rtLl8OM rtS202C rtM204V, and rtH248N, or yet another embodiment include rtI53V, rtS54T, rtN122T, rtM145L, rtLl80M, rtM204V and rtM250L, or yet another embodiement rtN53D, rtS85A, rtSIl6P, rtDl34V, rtNl39E/K, 10 rtQl49K, rtAI81V, rtS219A, rtl233V, rtN236T, rtM250L or a combination thereof or an equivalent mutation. Particularly useful mutants are at codons rtTl84, rtS202, rtS219, rt1233, rtl]248 or rtM250 scuh as rtTl84S, rtS202C, rtS219A, rtl233V, rt-1248N or rtM250L. 15 Useful mutations in the S gene include, in one embodiment include mutations at codons stT45, sL173, sL175, s1195, sTl18, sPl20, sPl27, s1195, sT114, S1195, sS204, s1208, sS210, sVI4, sG130, sM133, sW172, sS204 or sS210 such as sT45K, sL173L/F, sL175F, s1195M, in another embodiment include sTI18A, sP120T, sP127A and sI195M or yet 20 another emdodiment include sTl 14P, sl195M, sS204N, sl208T and sS21OR and finally another embodiment include sV I 4A, sG130R, sM I 33T, sW172L, sS204G, sS2IOR. The present invention further contemplates a method for determining the potential for an HBV to exhibit reduced sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV 25 and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and 30 TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or C \NRPonhN\CC\AAR\43"6)3 1_ DOC.4M/2112 -9 combinations thereof by isolating DNA or corresponding mRNA from the HBV and screening for a mutation in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in any one or more of domains F and G and domains A through to E or a region proximal thereto of the 5 DNA polymerase and associated with resistance or decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and 10 FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. With the proviso that the -IBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. 15 The presence of such a mutation is an indication of the likelihood of resistance to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, 20 ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. 25 The present invention also provides a composition comprising a variant HBV resistant to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and 30 LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and C \NRPonb\DCC\AAR\430693 _ LDOC-4/5/2012 - 10 ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof or an HBV surface antigen from the variant HBV or a recombinant or derivative form thereof or its chemical 5 equivalent and one or more pharmaceutically acceptable carriers and/or diluents. With the proviso that the HBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. Yet another aspect of the present invention provides a use of the aforementioned 10 composition or a variant HBV comprising a nucleotide mutation in a gene encoding a DNA polymerase resulting in at least one amino acid addition, substitution and/or deletion to the DNA polymerase and a decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; [TV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and 15 FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti 20 HBV agents or combinations thereof in the manufacture of a medicament for the treatment and/or prophylaxis of hepatitis B virus infection. With the proviso that the HBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. The present invention also contemplates a method for determining whether an 1-BV strain 25 exhibits reduced sensitivity to a nucleoside or nucleotide analog or other anti-HBV agents or by isolating DNA or corresponding mRNA from the -IBV and screening for a mutation in the nucleotide sequence encoding the DNA polymerase wherein the presence of the following mutations in the rt region: in one embodiment, mutations at codons rtN53, rtY54, rtLI80, rtTl81, rtTl84, rtM204, rtN236, rtYl24, rtl-1126, rtTl128, rtSl35, rtLl80, 30 rtS202, rtM204, rtH248, rt153, rtS54, rtN122, rtMl45, rtLl80, rtM204, rtM250, rIN53, rtS85, rtSl16, rtD134, rtNl39, rtQl49, rtAl8l, rtS219, rtl233, rtN236 or rtM250.

CNRPonbrlDCC\AAR4II 1931_I DOC-4IIIS/lI12 Particular mutants include rtN53, rtN53, rtY54, rtLl80, rt'181, rtTl84, rtM204, and rtN236, in another embodiment include rtYl24, rtl-1126, rtTl28, rtSl35, rtLl80, rtS202, rtM204, and rtH248, or yet another embodiment include rt153, rtS54, rtN122, rtMl45, rtL180, rtM204 and rtM250, or yet another embodiement rtN53, rtS85, rtSl16, rtD134, 5 rtN139, rtQl49, rtA181, rtS219, rt1233, rtN236, rtM250 or a combination thereof or an equivalent mutation. Even more particular mutants include rtN53K, rtN53KIN, rtY54D, rtLl80M, rtT181A/V, rtT184S, rtM204V, and rtN236T, in another embodiment include rtYl24H, rtH126R, rtTl28N, rtS135C, rtL180M rtS202C rtM204V, and rtH248N, or yet another embodiment include rtl53V, rtS54T, rtN122T, rtM145L, rtL180M, rtM204V and 10 rtM250L, or yet another embodiement rtN53D, rtS85A, rtSl 16P, rtDI34V, rtNl39E/K, rtQI49K, rtA181V, rtS219A, rtl233V, rtN236T, rtM250L or a combination thereof or an equivalent mutation. The mutations may also be a combination thereof or an equivalent mutation which mutation(s) is/are indicative of a variant which exhibits a decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; 15 FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and 20 LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. With the proviso that the HBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. 25 Still a further aspect provides a method for determining whether an HBV strain exhibits reduced sensitivity to a nucleoside or nucleotide analog said method comprising screening for a mutation in the nucleotide sequence encoding the envelope genes (s) wherein the presence of the following mutations in the s gene: in one embodiment include mutations at codons stT45, sL173, sL175, sI195, sTl18, sP120, sP127, sl195, sTI 14, Sl195, sS204, 30 s1208, sS210, sV14, sG130, sM133, sW172, sS204 or sS210 such as sT45K, sL173L/F, sL175F, sI195M and in another embodiment include and sTI 18A, sP120T, sP127A and C \NRPorbhDCC\AAR\J I6911_I DOC-4/05/2012 - 12 s1195M, or yet another embodiment include sT1 14P, sl195M, sS204N, sl208T, and sS210R, or still yet another embodiment include sV14A, sG130R, sMl33T, sW172L, sS204G, sS21OR or a combination thereof or an equivalent mutation or combinations thereof or an equivalent one or more other mutation is indicative of a variant which 5 exhibits a decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and 'FV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC 10 and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and FTV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof, and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combination thereof. With the proviso that the IBV variant does not 15 exhibit resistance to ETV alone or ETV or LMV alone. Preferably, the variants are in an isolated form such that they have undergone at least one purification step away from naturally occurring body fluid. Alternatively, the variants may be maintained in isolated body fluid or may be in DNA form. The present invention also 20 contemplates infectious molecular clones comprising the genome or parts thereof from a variant IBV. The detection of IBV or its components in cells, cell lysates, cultured supernatant fluid and bodily fluid may be by any convenient means including any nucleic acid-based detection means, for example, by nucleic acid hybridization techniques or via one or more polymerase chain reactions (PCRs). The term "bodily fluid" includes any fluid 25 derived from the blood, lymph, tissue or organ systems including serum, whole blood, biopsy and biopsy fluid, organ explants and organ suspension such as liver suspensions. Another aspect of the present invention is directed to a variant HBV comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, 30 addition and/or deletion or a truncation compared to a surface antigen from a reference or wild type HIBV and wherein an antibody generated to the reference or wild type surface CANRPortbl\DCC\AAR\4h691 _1. DOC-/I5/201 2 - 13 antigen exhibits an altered immunological profile relative to the HIBV variant. One altered profile includes a reduced capacity for neutralizing the HBV. More particularly, the surface antigen of the variant IBV exhibits an altered immunological profile compared to a pre-treatment HBV where the variant -IBV is selected for by a nucleoside or nucleotide 5 analog or other anti-HBV agents of the IBV DNA polymerase. The variant IBV of this aspect of the invention may also comprise a nucleotide sequence comprising a single or multiple nucleotide substitution, addition and/or deletion compared to a pre-treatment HBV. 10 The present invention further contemplates a method for detecting a variant HBV exhibiting an altered immunological profile said method comprising isolating an -IBV from a subject exposed to a nucleoside or nucleotide analog or combination of analogs selected from the listed consisting of ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; 15 ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV: ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV 20 and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof, and then contacting said -IBV with a panel of one or more antibodies to a surface antigen and screening for any change in binding affinity or binding spectrum. With the proviso that the -IBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. 25 In a related invention, the present invention provides a method for detecting a variant HBV exhibiting an altered immunological profile said method comprising isolating a serum sample from a subject exposed to a nucleoside or nucleotide analog selected from the listed consisting of ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; 30 FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; [TV and FTC; EIV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; C.\NRPonblDCC\AAR\ l 106 _ 1 DOC-4/5/2U 12 - 14 ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other 5 nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof, and then contacting the serum with a panel of I-IBV surface antigens or antibody-binding fragments thereof and screening for any change in binding affinity or binding spectrum. With the proviso that the HBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. 10 The present invention extends to an isolated -IBsAg or a recombinant form thereof or derivative or chemical equivalent thereof corresponding to the variant -1BV. Generally, the 1-BsAg or its recombinant or derivative form or its chemical equivalent comprises an amino acid sequence with a single or multiple amino acid substitution, addition and/or 15 deletion or a truncation compared to an -IBsAg from a reference -1BV and wherein an antibody directed to a reference HBV exhibits an altered immunological profile to an IBV carrying said variant HIBsAg. In one embodiment, the altered immunological profile comprises a reduction in the ability to neutralize the variant -IBV. 20 Another aspect of the present invention contemplates a method for detecting an agent which exhibits inhibitory activity to an HBV by generating a genetic construct comprising a replication competent-effective amount of the genome from the -IBV contained in a plasmid vector and then transfecting said cells with said construct, contacting the cells, before, during and/or after transfection, with the agent to be tested, culturing the cells for a 25 time and under conditions sufficient for the HBV to replicate, express genetic sequences and/or assemble and/or release virus or virus-like particles if resistant to said agents: and the subjecting the cells, cell lysates or culture supernatant fluid to viral- or viral component-detection means to determine whether or not the virus has replicated, expressed genetic material and/or assembled and/or been released in the presence of the agent. In a 30 preferred embodiment, the plasmid vector in a baculovirus vector and the method comprises generating a genetic construct comprising a replication competent-effective C NRP MTn)CCAAR\43t931- IDOC-4/012012 - 15 amount of the genome from the IBV contained in or fused to an amount of a baculovirus genome effective to infect cells and then infecting said cells with said construct, contacting the cells, before, during and/or after infection, with the agent to be tested, culturing the cells for a time and under conditions sufficient for the HBV to replicate, express genetic 5 sequences and/or assemble and/or release virus or virus-like particles if resistant to said agent and then subjecting the cells, cell lysates or culture supernatant fluid to viral- or viral-component-detection means to determine whether or not the virus has replicated, expressed genetic material and/or assembled and/or been released in the presence of the agent. 10 In connection with these methods, the plasmid vector may include genes encoding part or all of other viral vectors such as baculovirus vectors or adenovirus vectors (see Ren and Nassal, J. Virol. 75(3): 1104-1116, 2001). 15 In an alternative embodiment, the method comprises generating a continuous cell line comprising an infectious copy of the genome of the HBV in a replication competent effective amount such that said infectious HBV genome is stably integrated into said continuous cell line such as but not limited to the 2.2.15 or AD cell line, contacting the cells with the agent to be tested, culturing the cells for a time and under conditions 20 sufficient for the H4BV to replicate, express genetic sequences and/or assemble and/or release virus or virus-like particles if resistant to the agent and then subjecting the cells, cell lysates or culture supernatant fluid to viral- or viral-component-detection means to determine whether or not the virus has replicated, expressed genetic material and/or assembled and/or been released in the presence of the agent. 25 In an alternative embodiment, the present invention also contemplates a method for detecting an agent which exhibits inhibitory activity to an HIBV polymerase in an in vitro polymerase assay. The HBV polymerase activity can be examined using established assays (Gaillard et al., Antimicrob Agents Chemother. 46(4): 1005-1013, 2002; Xiong et al., 30 Hepatology. 28(6): 1669-73, 1998). The HBV polymerase may be a wild-type or reference HBV polymerase or mutant IBV polymerase.

C WNRPonbl\DCC\AAR\43693 1_lDOC-4/05/2012 -16 The identification of viral variants enables the production of vaccines comprising particular recombinant viral components such as polymerases or envelope genes PreSl, PreS2, S encoding for L, M, S proteins as well as therapeutic vaccines comprising 5 defective -1BV variants. Rational drug design may also be employed to identify or generate therapeutic molecules capable of interacting with a polymerase or envelope genes PreS 1, PreS2, S encoding for L, M, S proteins or other component of the HBV. Such drugs may also have diagnostic potential. In addition, defective HBV variants may also be used as therapeutic compositions to generate an immune response against the same, similar or 10 homologous viruses. Alternatively, antibodies generated to the HBV variants or surface components thereof may be used in passive immunization of subjects against infection by -IBV variants or similar or homologous viruses. Furthermore, agents such as nucleoside or nucleotide analogs, RNAi or siRNA molecules (both DNA-derived or synthetic), antisense or sense oligonucleotides, chemical or proteinaceous molecules having an ability to down 15 regulate the activity of a component of IBV and inhibit replication, maintenance, infection, assembly or release are contemplated by the present invention. As indicated above, the present invention does not extend to an -IBV variant exhibiting resistance or reduced sensitivity to ETV alone or ETV and LMV alone. 20 A summary of the abbreviations used throughout the subject specification are provided in Table 3. A summary of sequence identifiers used throughout the subject specification is provided in 25 Table 1.

C:\NRPorbl\DCC\AAR\. 169.1_I DOC-4/'512012 - 17 TABLE 1 Summary of sequence identifiers SEQUENCE ID NO: DESCRIPTION I PCR primer 2 PCR primer 3 PCR primer 4 PCR primer 5 PCR primer 6 Nucleotide sequence of catalytic region of polymerase from resistant HBV Patient A: Sample A 7 Deduced amino acid sequence of catalytic region of polymerase resistant HBV Patient A: Sample A 8 Dedecuded amino acid sequence of envelope gene from resistant HBV from Pateint A: Sample A 9 Nucleotide sequence of catalytic region of polymerase from resistant IBV Patient A: Sample B 10 Dedecuded amino acid sequence of envelope gene from resistant HBV from Pateint A: Sample B 11 Dedecuded amino acid sequence of envelope gene from resistant HBV from Pateint A: Sample B 12 Nucleotide sequence of catalytic region of polymerase from resistant IBV Patient B 13 Deduced amino acid sequence of catalytic region of polymerase resistant HBV Patient B 14 Dedecuded amino acid sequence of envelope gene from resistant HBV from Pateint B 15 Nucleotide sequence of catalytic region of polymerase from resistant IBV Patient C 16 Deduced amino acid sequence of catalytic region of polymerase resistant HBV Patient C 17 Dedecuded amino acid sequence of envelope gene from resistant HBV from Pateint C 18 Nucleotide sequence of catalytic region of polymerase from resistant IBV Patient D 19 Deduced amino acid sequence of catalytic region of polymerase resistant HBV Patient D 20 Dedecuded amino acid sequence of envelope gene from resistant 1-BV from Pateint D C \NRPonbnDCC\AAR\43I(") I DOC-4 12012 - 18 TABLE 2 Single and three letter amino acid abbreviations Amino Acid Three-letter Abbreviation One-letter symbol Alanine Ala A Arginine Arg R Asparagine Asn N Aspartic acid Asp D Cysteine Cys C Glutamine Gin Q Glutamic acid Glu E Glycine Gly G Histidine His Hi Isoleucine lie Leucine Leu L Lysine Lys K Methionine Met M Phenylalanine Phe F Proline Pro P Serine Ser S Threonine The T Tryptophan Trp W Tyrosine Tyr Y Valine Val V Any residue Xaa X C NRPonbl\DCC\AAR\4316)31_ DOC4/5/210)2 - 19 TABLE 3 Abbreviations ABBREVIATION DESCRIPTION 3TC (LMV); (-)-p-2'-deoxy-3'-thiacytidine ADV adefovir dipivoxil DAPD diaminopurine dioxalone DXG dioxolane guanine ETV entecavir FAM famciclovir FCV famciclovir FTC emtricitabine HBIG hepatitis B immunoglobulin HBsAg hepatitis B surface antigen HBV hepatitis B virus LMV lamividuine PMEA 9-[phosphonyl-methoxyethyl]-adenine; adefovir PMPA 9-R-(2-phosphonomethoxypropyl)adenine RNase ribonuclease rt ("rt" before "XaainXaa 2 " means reverse transcriptase reverse transcriptase) s (as used in a mutation, envelope gene e.g. sF I 34V) TFV tenofovir disoproxil fumarate YMDD Tyr Met Asp Asp-a motif in the polymerase protein; where the Met residue is designated residue number 204 of the reverse transcriptase 5 C:\NRPonblDCC\AAR\416931 -1 DOC-4/1U5/2112 - 20 BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a diagrammatic representation showing the partially double stranded DNA HlBV genome showing the overlapping open reading frames encoding surface (S), core 5 (C), polymerase (P) and X gene. Figure 2 is a diagrammatic representation of the chemical structure of ADV. Figure 3 is a representation showing comparison of the HBV nucleotide sequence 10 encoding the catalytic region of the polymerase gene in sequential samples from Patient A during ADV treatment (sample A). Figure 4 is a representation showing comparison of the deduced amino acid sequence of the catalytic region of the polymerase gene in sequential samples from Patient A during 15 ADV therapy (sample A).. Figure 5 is a representation showing comparison of the deduced amino acid sequence of the envelope gene in sequential samples from Patient A during ADV therapy (sample A). 20 Figure 6 is a representation showing comparison of the HBV nucleotide sequence encoding the catalytic region of the polymerase gene in sequential samples from Patient A during ADV treatment (sample B). Figure 7 is a representation showing comparison of the deduced amino acid sequence of 25 the catalytic region of the polymerase gene in sequential samples from Patient A during ADV therapy (sample B). Figure 8 is a representation showing comparison of the deduced amino acid sequence of the envelope gene in sequential samples from Patient A during ADV therapy (sample B). 30 CNRPorbiIDCC\AAR\4311_I DOC-4aIM21112 -21 Figure 9 is a representation showing comparison of the H-BV nucleotide sequence encoding the catalytic region of the polymerase gene in sequential samples from Patient B during ADV and LMV treatment. 5 Figure 10 is a representation showing comparison of the deduced amino acid sequence of the catalytic region of the polymerase gene in sequential samples from Patient B during ADV and LMV therapy. Figure 11 is a representation showing comparison of the deduced amino acid sequence of 10 the envelope gene in sequential samples from Patient B during ADV and LMV therapy. Figure 12 is a representation the HBV nucleotide sequence encoding the catalytic region of the polymerase gene in samples from Patient C during ADV treatment. 15 Figure 13 is a representation the deduced amino acid sequence of the catalytic region of the polymerase gene in samples from Patient C during ADV therapy. Figure 14 is a representation the deduced amino acid sequence of the envelope gene in samples from Patient C during ADV therapy. 20 Figure 15 is a graphical representation of increase in HBV DNA levels (viral load) and ALT over time (days since the initation of the first antiviral therapy). Figure 16 is a representation the lBV nucleotide sequence encoding the catalytic region 25 of the polymerase gene in samples from Patient D during ADV and LMVtreatment. Figure 17 is a representation the deduced amino acid sequence of the catalytic region of the polymerase gene in samples from Patient D during ADV and LMV therapy. 30 Figure 18 is a representation the deduced amino acid sequence of the envelope gene in samples from Patient D during ADV and LMV therapy.

CANRPonblU\ CCAARW 3069 1_1 DOC-/521 12 - 22 DETAILED DESCRIPTION OF THE INVENTION The present invention is predicated in part on the identification and isolation of nucleoside or nucleotide analog-resistant variants of HBV following treatment of patients with either 5 ADV or LMV or ETV or more particularly ADV and LMV or TFV and LMV, or ETV and optionaly one or more other nucleoside analogs or nucleotide analogs or other anti--IBV agents such as TFV or FTC. In particular, ADV or ADV and LMV or ETV treated patients gave rise to variants of HBV exhibiting decreased or reduced sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and 10 TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and 15 FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. With the proviso that the -IBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. Reference herein to "decreased" or "reduced" in relation to sensitivity to ADV and/or LMV and/or FTC and/or TFV and/or ETV includes and encompasses a complete or substantial resistance to the 20 nucleoside or nucleotide analog or other anti-IBV agents as well as partial resistance and includes a replication rate or replication efficiency which is more than a wild-type in the presence of a nucleoside or nucleotide analog or other anti--IBV agents. In one aspect, this is conveniently measured by an increase in viral load during treatment, or alternatively, there is no substantial decrease in HBV DNA viral load from pre-treatment HBV DNA 25 levels during treatment (i.e., non-response to treatment). Accordingly, one aspect of the present invention provides an isolated hepatitis B virus (HBV) variant wherein said variant comprises a nucleotide mutation resulting in an amino acid addition, substitution and/or deletion in a protein encoded by said variant and wherein 30 said variant exhibits decreased sensitivity to one or more nucleoside or nucleotide analogs selected from the list consisting of ADV, LMV, TFV or FTC; ADV and LMV; ADV and C \NRPorblDCC\AAR\430691 -I DOC-4/n5/2012 - 23 TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and 1V; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and 'TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC 5 and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; and ADV and FTC and LMV and TFV and ETV. In particular, the mutations are in the DNA polymerase or surfce antigen (S gene product). 10 Accordingly, one aspect of the present invention contemplates an isolated Hepatitis B virus (HBV) variant wherein said variant comprises a nucleotide mutation in a gene encoding a DNA polymerase resulting in at least one amino acid addition, substitution and/or deletion to said DNA polymerase and wherein said variant exhibits decreased sensitivity to one or 15 more nucleoside or nucleotide analogs selected from the list consisting of ADV, [MV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and 20 FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. 25 A further aspect of the present invention provides a method for determining the potential for an HBV to exhibit reduced sensitivity to a nucleoside or nucleotide analog selected from ADV, LMV, TFV and FTC or ETV and another analog except [MV or a combination thereof or optionally other nucleoside or nucleotide analogs, said method comprising isolating DNA or corresponding mRNA from said -IBV and screening for a 30 mutation in the nucleotide sequence encoding -IBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in any one or more of domains F and C.\NRPorlbl\DCC\AAR\43W6931_ DOC-4.05/2012 - 24 A through E or a region proximal thereto of said DNA polymerase and associated with resistance or decreases sensitivity to one or more of ADV, LMV, TFV, FTC and/or wherein the presence of such a mutation is an indication of the likelihood of resistance to said one or more of ADV, LMV, TFV and/or FTC and/or ETV and another nucleoside or 5 nucleotide analog except LMV. Before describing the present invention in detail, it is to be understood that unless otherwise indicated, the subject invention is not limited to specific formulations of components, manufacturing methods, dosage regimens, or the like, as such may vary. It is 10 also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. It must be noted that, as used in the subject specification, the singular forms "a", "an" and "the" include plural aspects unless the context clearly dictates otherwise. Thus, for 15 example, reference to "a nucleoside or nucleotide analog" includes a single analog, as well as two or more analogs; reference to "an -IBV variant" includes reference to two or more IBV variants; and so forth. In describing and claiming the present invention, the following terminology is used in 20 accordance with the definitions set forth below. The terms "analog", "compound", "active agent", "'pharmacologically active agent", "medicament", "active" and "drug" are used interchangeably herein to refer to a chemical compound that induces a desired effect such as inhibit viral replication, infection, 25 maintenance, assembly and/or the function of an enzyme such as HBV DNA polymerase. The terms also encompass pharmaceutically acceptable and pharmacologically active ingredients of those active agents specifically mentioned herein including but not limited to salts, esters, amides, prodrugs, active metabolites, analogs and the like. When the terms "analog", "compound", "active agent", "pharmacologically active agent", "medicament", 30 "active" and "drug" are used, then it is to be understood that this includes the active agent per se as well as pharmaceutically acceptable, pharmacologically active salts, esters, C.NRPorl\IDCCAAR\4,911_1 DOC-4/05/2012 - 25 amides, prodrugs, metabolites, analogs, etc. The present invention contemplates, therefore, compounds useful in inhibiting HBV replication, infection, maintenance, assembly and/or the function of an enzyme such as 5 HBV DNA polymerase. Reference to an "analog", "compound", "active agent", "pharmacologically active agent", "medicament", "active" and "drug" such as ADV, LMV, TFV, ETV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and LMV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and 10 LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and [MV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. 15 A "combination" also includes a two-part or more such as a multi-part anti--IBV therapeutic composition where the agents are provided separately and given or dispensed separately or admixed together prior to dispensation. The terms "effective amount" and "therapeutically effective amount" of an agent as used 20 herein mean a sufficient amount of the agent to provide the desired therapeutic or physiological effect of inhibiting HBV replication, infection, maintenance, assembly and/or the function of an enzyme such as HBV DNA polymerase. Furthermore, an "effective HBV-inhibiting amount" or "effective symptom-ameloriating amount" of an agent is a sufficient amount of the agent to directly or indirectly inhibit replication, 25 infection, maintenance, assembly and/or the function of an enzyme such as HBV DNA polymerase. Undesirable effects, e.g. side effects, are sometimes manifested along with the desired therapeutic effect; hence, a practitioner balances the potential benefits against the potential risks in determining what is an appropriate "effective amount". The exact amount required will vary from subject to subject, depending on the species, age and general 30 condition of the subject, mode of administration and the like. Thus, it may not be possible to specify an exact "effective amount". However, an appropriate "effective amount" in any C \NRPobl\DCCAARW1 l.93 [ DOC-mV2I12 - 26 individual case may be determined by one of ordinary skill in the art using only routine experimentation. By "pharmaceutically acceptable" carrier, excipient or diluent is meant a pharmaceutical 5 vehicle comprised of a material that is not biologically or otherwise undesirable, i.e. the material may be administered to a subject along with the selected active agent without causing any or a substantial adverse reaction. Carriers may include excipients and other additives such as diluents, detergents, coloring agents, wetting or emusifying agents, p-I buffering agents, preservatives, and the like. 10 Similarly, a "pharmacologically acceptable" salt, ester, emide, prodrug or derivative of a compound as provided herein is a salt, ester, amide, prodrug or derivative that this not biologically or otherwise undesirable. 15 The terms "treating" and "treatment" as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage in relation to HBV infection. Thus, for example, "treating" a patient involves prevention of HBV infection as well as treatment of a clinically HBV 20 symptomatic individual by inhibiting HBV replication, infection, maintenance, assembly and/or the function of an enzyme such as IBV DNA polymerase. Thus, for example, the present method of "treating" a patient with IBV infection or with a propensity for one to develop encompasses both prevention of IBV infection as well as treating H1BV infection or symptoms thereof. In any event, the present invention contemplates the treatment or 25 prophylaxis of HBV infection. "Patient" as used herein refers to an animal, preferably a mammal and more preferably a primate including a lower primate and even more preferably, a human who can benefit from the formulations and methods of the present invention. A patient regardless of 30 whether a human or non-human animal may be referred to as an individual, subject, animal, host or recipient. The compounds and methods of the present invention have C\NRPonblDCC\AAR\43l6931_1 DOC-4IS/2ln 12 - 27 applications in human medicine, veterinary medicine as well as in general, domestic or wild animal husbandry. For convenience, an "animal" includes an avian species such as a poultry bird (including ducks, chicken, turkeys and geese), an aviary bird or game bird. The condition in a non-human animal may not be a naturally occurring HBV infection but 5 HBV-like infection may be induced. As indicated above, the preferred animals are humans, non-human primates such as marmossets, baboons, orangatangs, lower primates such as tupia, livestock animals, laboratory test animals, companion animals or captive wild animals. A human is the most 10 preferred target. However, non-human animal models may be used. Examples of laboratory test animals include mice, rats, rabbits, guinea pigs and hamsters. Rabbits and rodent animals, such as rats and mice, provide a convenient test system or animal model as do primates and lower primates. Livestock animals include sheep, cows, 15 pigs, goats, horses and donkeys. Non-mammalian animals such as avian species, zebrafish, amphibians (including cane toads) and Drosophila species such as Drosophila melanogasler are also contemplated. Instead of a live animal model, a test system may also comprise a tissue culture system. 20 An "anti-HBV agent" includes a nucleoside or nucleotide analog, protein, chemical compound, RNA or DNA or RNAi or siRNA oligonucleotide (either DNA-derived or synthetic). Preferably, the decreased sensitivity is in respect of ETV. Alternatively, the decreased 25 sensitivity is in respect of ADV or LMV. Alternatively, the decreased sensitivity is in respect of TFV. Alternatively, the decreased sensitivity is in respect of FTC. Alternatively, the decreased sensitivity is in respect of ETV and another nucleotide or nucleoside analog with the exception of LMV alone. Alternatively, the decreased sensitivity is in respect of ADV and TFV and optionally ETV. Alternatively, the decreased sensitivity is in respect of 30 LMV and TFVand optionally ETV. Alternatively, the decreased sensitivity is in respect of ADV and FTC and optionally ETV. Alternatively, the decreased sensitivity is in respect to C RPonbl\DCCAARU1-fl -I1 DOC-4/0512012 - 28 FTC and TFV and optionally ETV. Alternatively, the decreased sensitivity is in respect of FTC and LMV and optionally ETV. Alternatively, the decreased sensitivity is in respect of ADV and LMV and TFV and optionally ETV. Alternatively, the decreased sensitivity is in respect to ADV and TFV and FTC and optionally ETV. Alternatively, the decreased 5 sensitivity is in respect to LMV and TFV and FTC and optionally ETV. Alternatively, the decrease sensitivity is in respect of ADV and LMV and FTC and optionally ETV. Alternatively, the decreased sensitivity is in respect of ADV and FTC and TFV and LMV and optionally ETV. The present invention does not extend to an -IBV variant exhibiting resistance or reduced sensitivity to ETV alone or ETV and LMV alone. 10 Reference herein to "anti--IBV agents" includes nucleoside and nucleotide analogs as well as immunological reagents (e.g. antibodies to IBV surface components) and chemical, proteinaceous and nucleic acid agents which inhibit or otherwise interfere with viral replication, maintenance, infection, assembly or release. Reference herein to "nucleic acid" 15 includes reference to a sense or antisense molecule, RNA or DNA, oligonucleotides and RNAi and siRNA molecules and complexes containing same. In addition to a mutation in the gene encoding DNA polymerase, due to the overlapping nature of the -IBV genome (Figure 1), a corresponding mutation may also occur in the 20 gene encoding the S gene encoding the surface antigen (HBsAg) resulting in reduced interactivity of immunological reagents such as antibodies and immune cells to 1BsAg. The reduction in the interactivity of immunological reagents to a viral surface component generally includes the absence of immunological memory to recognize or substantially recognize the viral surface component. The present invention extends, therefore, to an 25 HBV variant exhibiting decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV: ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and 30 TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV C:\NRorbl\DCC\AAR\U3M'|_I )DOC-4/0/2(12 - 29 and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti HBV agents or combinations thereof or a reduced interactivity of an immunological reagent to HBsAg wherein the variant is selected for following ADV and/or LMV combination or sequential treatment. The term "sequential" in this respect means ADV 5 followed by LMV and/or TFV and/or ETV, and /or FTC, LMV followed by ADV and/or TFV and /or FTC and/or ETV or ETV followed by one or more of ADV, FTC, LMV and/or TFV, or multiple sequential administrations of each of ETV, ADV, LMV and/or TFV and lor FTC. With the proviso that the -IBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. 10 A viral variant may, therefore, carry A mutation only in the DNA polymerase gene or both in the DNA polymerase gene and the S gene. The term "mutation" is to be read in its broadest context and includes multiple mutations. 15 The present invention extends to a mutation and any domain of the HBV DNA polymerase and in particular regions F and G, and domains A through to E provided said mutation leads to decreased sensitivity to ADV and/ or LMV and/or TFV and/or ETV and/or FTC or combinations thereof. 20 In this specification, reference is particularly made to the conserved regions of the DNA polymerase as defined by domains A to lE. Regions A to E are defined by the amino acid sequence set forth in Formula II in Australian Patent No. 734831. Preferably, the mutation results in an altered amino acid sequence in any one or more of 25 domains F and G, and domains A through to E or regions proximal thereto of the HBV DNA polymerase. Another aspect of the present invention provides an -IBV variant comprising a mutation in an overlapping open reading frame in its genome wherein said mutation is in a region 30 defined by one or more of domains F and G, and domains A through to E of HBV DNA polymerase and wherein said variant exhibits decreased sensitivity to ADV, LMV, TFV or C.\NRPortbl\DCC\AAR\430693)_I-DOC-515212 - 30 FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and 5 LMV and TFV; ETV and FTC and LMV and TFV; ADV and [EIV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. With the proviso that the IBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. 10 Another preferred aspect of the present invention contemplates an HBV variant comprising a mutation in the nucleotide sequence encoding HBsAg resulting in an amino acid addition, substitution and/or deletion in said H-lBsAg wherein said variant exhibits decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV 15 and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV: ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and 20 FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti--IBV agents or combinations thereof. With the proviso that the HBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. 25 More particularly, the present invention provides a variant HBV comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or a truncation compared to a surface antigen from a reference or wild-type IBV and wherein an antibody generated to the reference or wild-type surface antigen exhibits reduced capacity for neutralizing said HBV variant, said variant selected 30 by exposure of a subject to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; [TV and C W PonbI\DCC\AAR\41(K II_ DOC-4/521112 -31 FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV: ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV: ADV 5 and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti--IBV agents or combinations thereof. With the proviso that the IBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. 10 The term "combination therapy" means that both combinations of ADV, LMV, FTC, TFV, and/or ETV are co-administered in the same composition or simultaneously in separate compositions. The term "sequential therapy" means that the two agents are administered within seconds, minutes, hours, days or weeks of each other and in either order. Sequential therapy also encompasses completing a therapeutic course with one or other of ADV, 15 LMV, FTC, TFV or ETV and then completing a second or third or subsequent therapeutic courses with the other of ADV, LMV, FTC, TFV or ETV. Accordingly, another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple 20 amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HBV and wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment HBV where the said variant HBV is selected for by exposure of a subject to ADV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-HBV agents. 25 Another aspect of the present invention contemplates an I-I BV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment I-lBV and wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to 30 the pretreatment IBV where the said variant HBV is selected for by exposure of a subject C.\NRPonblU)CC\AAR 10693| I DOC-4/0/2 12 - 32 to LMV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-IBV agents. Yet another aspect of the present invention contemplates an IBV variant comprising a 5 surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment IBV and wherein the surface antigen of the variant IBV exhibits an altered immunological profile compared to the pretreatment IBV where the said variant HIBV is selected for by exposure of a subject to FTC therapy or therapy by one or more other nucleoside or nucleotide 10 analogs or other anti--IBV agents. Still another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HBV and 15 wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment HBV where the said variant IBV is selected for by exposure of a subject to TFV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-HBV agents. 20 Yet still another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment IBV and wherein the surface antigen of the variant 1-11V exhibits an altered immunological profile compared to the pretreatment HBV where the said variant HBV is selected for by exposure 25 of a subject to ETV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-HBV agents. Even yet another aspect of the present invention contemplates an IBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid 30 substitution, addition and/or deletion or truncation compared to the pretreatment IBV and wherein the surface antigen of the variant IBV exhibits an altered immunological profile C:\NRotbl\DCCA A RU'M9 DOC-1/05/2012 - 33 compared to the pretreatment HBV where the said variant IBV is selected for by exposure of a subject to ADV and LMV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-l-BV agents. 5 Even still another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HBV and wherein the surface antigen of the variant IBV exhibits an altered immunological profile compared to the pretreatment HBV where the said variant HBV is selected for by exposure 10 of a subject to ADV and TFV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-HBV agents. Yet still another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid 15 substitution, addition and/or deletion or truncation compared to the pretreatment -13V and wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment I-lBV where the said variant HBV is selected for by exposure of a subject to ADV and ETV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-HBV agents. 20 A further aspect of the present invention contemplates an IBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment -IBV and wherein the surface antigen of the variant HIBV exhibits an altered immunological profile 25 compared to the pretreatment IBV where the said variant IBV is selected for by exposure of a subject to LMV and TFV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti--IBV agents. Yet a further aspect of the present invention contemplates an IBV variant comprising a 30 surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment -IBV and CANRPonb\)CC\AAR\43(0M931_ DOC-/0512012 - 34 wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment HBV where the said variant -IBV is selected for by exposure of a subject to LMV and ETV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-HBV agents. 5 Another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HIBV and wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to 10 the pretreatment IBV where the said variant -IBV is selected for by exposure of a subject to ADV and FTC therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-I-BV agents. Yet another aspect of the present invention contemplates an HBV variant comprising a 15 surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment IBV and wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment IBV where the said variant HBV is selected for by exposure of a subject to TFV and FTC therapy or therapy by one or more other nucleoside or 20 nucleotide analogs or other anti-HBV agents. Still another aspect another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the 25 pretreatment iBV and wherein the surface antigen of the variant IBV exhibits an altered immunological profile compared to the pretreatment IBV where the said variant IBV is selected for by exposure of a subject to TFV and ETV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti--IBV agents. 30 Still another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid C.\NRPorbl\C\AAR\4 0|_I DOC-4;5/2012 - 35 substitution, addition and/or deletion or truncation compared to the pretreatment HBV and wherein the surface antigen of the variant IBV exhibits an altered immunological profile compared to the pretreatment HBV where the said variant HBV is selected for by exposure of a subject to FTC and LMV therapy or therapy by one or more other nucleoside or 5 nucleotide analogs or other anti-HBV agents. Even another aspect of the present invention contemplates an IBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HBV and 10 wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment HBV where the said variant HBV is selected for by exposure of a subject to FTC and ETV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-HBV agents. 15 Even yet another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HBV and wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment l-BV where the said variant lBV is selected for by exposure 20 of a subject to ADV, LMV and TFV and/or ETV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti--IBV agents. Even still another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid 25 substitution, addition and/or deletion or truncation compared to the pretreatment H1BV and wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment HBV where the said variant HBV is selected for by exposure of a subject to ADV, LMV and TFVand/or ETV therapy or therapy by one or more other nucleoside or nculeotide analogs or other anti-HBV agents. 30 C WNRPonbl\DCC\AAR\43931 -_DOC-/S5/2012 - 36 A further aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HBV and wherein the surface antigen of the variant IBV exhibits an altered immunological profile 5 compared to the pretreatment HBV where the said variant HBV is selected for by exposure of a subject to ADV, LMV and FTC and/or ETV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-I-lBV agents. Another aspect of the present invention contemplates an HBV variant comprising a surface 10 antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HBV and wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment HBV where the said variant IBV is selected for by exposure of a subject to FTC, LMV and TFV and/or ETV therapy or therapy by one or more other nucleoside or 15 nucleotide analogs or other anti--IBV agents. Yet another aspect of the present invention contemplates an IIBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HBV and 20 wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment IBV where the said variant HBV is selected for by exposure of a subject to ADV, FTC and TFV and/or ETV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-HBV agents. 25 Still yet another aspect of the present invention contemplates an HBV variant comprising a surface antigen having an amino acid sequence with a single or multiple amino acid substitution, addition and/or deletion or truncation compared to the pretreatment HBV and wherein the surface antigen of the variant HBV exhibits an altered immunological profile compared to the pretreatment HBV where the said variant lBV is selected for by exposure 30 of a subject to ADV, LMV, FTC and TFV and/or ETV therapy or therapy by one or more other nucleoside or nucleotide analogs or other anti-I-lBV agents.

C \NRPorbJ\DCC\AAR\43(93 I DOC-4'/21112 - 37 Preferably, the variants are in isolated form such that they have undergone at least one purification step away from naturally occurring body fluid. Alternatively, the variants may be maintained in isolated body fluid or may be in DNA form. The present invention also 5 contemplates infectious molecular clones comprising the genome or parts thereof from a variant HBV. Furthermore, the present invention provides isolated components from the variant HBVs such as but not limited to an isolated -BsAg. Accordingly, the present invention provides an isolated -BsAg or a recombinant form thereof or derivative or chemical equivalent thereof, said HBsAg being from a variant HBV selected by exposure 10 of a subject to one or more of ADV, LMV, FTC, TFV and/or ETV or optionally one or more nucleoside or nucleotide analogs or other anti-IBV agents. More particularly, yet another aspect of the present invention is directed to an isolated variant -BsAg or a recombinant or derivative form thereof or a chemical equivalent 15 thereof wherein said H-lBsAg or its recombinant or derivative form or its chemical equivalent exhibits an altered immunological profile compared to an HBsAg from a reference HBV, said HBsAg being from a variant HBV selected by exposure of a subject to one or more of ADV, LMV, FTC, TFV and/or ETV or optionally one or more nucleoside or nucleotide analogs or other anti-IBV agents. 20 Even more particularly, the present invention provides an isolated variant -BsAg or a recombinant or derivative form thereof or a chemical equivalent thereof wherein said H-BsAg or its recombinant or derivative form or its chemical equivalent comprises an amino acid sequence with a single or multiple amino acid substitution, addition and/or 25 deletion or a truncation compared to an 1-BsAg from a reference -1BV and wherein a neutralizing antibody directed to a reference B113V exhibits no or reduced neutralising activity to an IIBV carrying said variant -BsAg, said HiBsAg being from a variant -IBV selected by exposure of a subject to one or more of ADV, LMV, FTC, TFV and/or ETV or optionally one or more nucleoside or nucletoide analogs or other anti-HBV agents. 30 C.\NRPonbl\DCC\A AR\4-MI DOC-4/05/2.12 - 38 Preferred mutations in the HBV DNA polymerase include variants selected from patients with HBV recurrence following ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV 5 and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and iETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti--IBV agents or 10 combinations thereof. Nucleoside or nucleotide analogs or other anti-l-IBV agents may be indicated during , after or prior to a transplantation procedure (e.g. bone marrow transplantation (BMT) or OLT) or following treatment of patients diagnosed with hepatitis. Following selection of variants, viral loads are obtainable at levels similar to pre-treatment levels or increase while on therapy. 15 Useful mutants in the rt region include, in one embodiment, mutations at codons rtN53, rtY54, rtL180, rtTl81, rtT184, rtM204, rtN236, rtY124, rt-1126, rtTl28, rtSl35, rtLl80, rtS202, rtM204, rtH248, rt153, rtS54, rtN122, rtM145, rtL180, rtM204, rtM250, rtN53, rtS85, rtSl 16, rtD134, rtN139, rtQl49, rtA18l, rtS219, rt1233, rtN236 or rtM250such as 20 rtN53K, rtN53K/N, rtY54D, rtLl80M. rtTl8lA/V rtTl84S, rtM204V, and rtN236T, in another embodiment include rtYl24-1, rtl-1126R, rtTl28N, rtSl35C, rtLl80M rtS202C rtM204V, and rtH248N, or yet another embodiment include rIl53V, rtS54T, rtN122T, rtM145L, rtL180M, rtM204V and rtM250L, or still yet another embodiment include rtN53D, rtS85A, rtSll6P, rtD134V, rtN139E/K, rtQI49K, rtAl8lV, rtS219A, rtl233V, 25 rtN236T, rtM250L or a combination thereof or an equivalent mutation. Particularly useful mutants are rtT184S, rtS202C, rtS219A, rtl233V, rtH248N or rtM250L Such H-BV variants are proposed to exhibit a decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; 30 FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and C:\NRPornbLDCC\AAR\430601I DOC-4r/5/2012 - 39 ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or 5 other anti-HBV agents or combinations thereof and/or optionally other nucleoside or nucleotide analogs or other anti-H]BV agents or combination thereof. It should be noted that the nomenclature system for amino acid positions is based on the methionine residues in the YMDD motif being designated codon rtM204. This numbering system is different to that in Australian Patent No. 734831 where the methionine residue in the YMDD motif 10 within the polymerase gene is designated codon 550. In this regard, rtLI80M and rtM204V correspond to L526M and M550V, respectively, in Australian Patent No. 734831. Corresponding mutations may also occur in envelope genes such as in one or more of PreSI, PreS2 and S. 15 Another potential mode of action of ADV and other acyclic nucleoside phosphonates is that of immune stimulation (Calio el al.. Antiviral Res. 23: 77-89, 1994). A number of mutations resulted in changes in the envelope gene detected in -IBV variants which may be associated with immune escape. These changes include in one embodiment include in one embodiment includemutations at codons stT45, sLl73, sL175, sl195, sTI 18, sPl20, 20 sP127, sl195, sTi 14, S 1195, sS204, s1208, sS210, sV 14, sG130, sM 133, sW 172, sS204 or sS210 such as sT45K, sLI73L/F, sLI75F, sIl95M and in another embodiment include and sTI18A, sP12oT, sP127A and sl195M, or yet another embodiment include sT1141P, sI195M, sS204N, sl208T, and sS210R, or still yet another embodiment include sV14A, sG130R, sM133T, sW172L, sS204G, sS210R or a combination thereof or an equivalent 25 mutation, or a combination thereof or an equivalent mutation. The identification of the variants of the present invention permits the generation of a range of assays to detect such variants. The detection of such variants may be important in identifying resistant variants to determine the appropriate form of chemotherapy and/or to 30 monitor vaccination protocols, or develop new or modified vaccine preparations.

C\NRPonbflDCC\AAR M|_I DOC-15/2 12 - 40 Still another aspect of the present invention contemplates a method for determining the potential for an HBV to exhibit reduced sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and 5 FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti 10 IBV agents or combinations thereof and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in any one or more of domains F and G, and A domains through to 15 E or a region proximal thereto of said DNA polymerase and associated with resistance or decreased sensitivity to ADV, LMV, TFV, or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV 20 and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti--IBV agents or combinations thereof. With the proviso that the HBV variant does not exhibit resistance to ETV alone or ETV or 25 LMV alone. Accordingly, another aspect of the present invention provides a method for determining the potential for an HBV to exhibit reduced sensitivity to a nucleoside or nucleotide analog selected from ADV, LMV, TFV and FTC and ETV and another nucleotide or nucleoside 30 analog except LMV alone or optionally other nucleoside or nucleotide analogs, said method comprising isolating DNA or corresponding mRNA from said HBV and screening CNRPonbl\DCC\'AAR\A I .1. DOC-/TISf/212 -41 for a mutation in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in any one or more of domains F and A through E or a region proximal thereto of said DNA polymerase and associated with resistance or decreases sensitivity to one or more of ADV, LMV, TFV, FTC and/or ETV 5 wherein the presence of such a mutation is an indication of the likelihood of resistance to said one or more of ADV, LMV, TFV and/or FTC and/or ETV and another analog except LMV alone. With the proviso that the HBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. 10 Preferably, the assay detects one or more mutations at codons rtN53, rtY54, rtLl80, rtTl8l, rtTl84, rtM204, rtN236, rtY124, rtH126, rtTl28, rtSl35, rtLl80, rtS202. rtM204, rtH248, rtl53, rtS54, rtN122, rtM145, rtLl80, rtM204, rtM250, rtN53, rtS85, rtSl16, rtDl34, rtN139, rtQl49, rtAl8l, rtS219, rt1233, rtN236 or rtM250 such as rtN53K, rtN53KIN, rtY54D, rtLl80M, rtTl81A/V rtT184S, rtM204V, and rtN236T, in another 15 embodiment include rtYl24H, rtl-1126R, rtT128N, rtS135C, rtL180M rtS202C rtM204V, and rtl-1248N, or yet another embodiment include rtl53V, rtS54T, rtN122T, rtM145L, rtL180M, rtM204V and rtM250L, or still yet another embodiment include rtN53D, rtS85A, rtS116P, rtD134V, rtNl39E/K, rtQ149K, rtAl81V, rtS219A, rtl233V, rtN236T, rtM250L, or a combination thereof or an equivalent mutation is indicative of a variant wherein said 20 variant exhibits a decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV: FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV 25 and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof and/or optionally other nucleoside or nucleotide analogs or other anti-l-BV agents or combination thereof. 30 C:NRPonbl\DCC\AAR\43"(93 I1,OC4/5/2012 - 42 Accordingly, another aspect of the present invention produces a method for determining whether an IBV strain exhibits reduced sensitivity to a nucleoside or nucleotide analog or other anti-HBV agents, said method comprising isolating DNA or corresponding mRNA from said IBV and screening for a mutation in the nucleotide sequence encoding the DNA 5 polymerase and/or a corresponding region of the S gene, wherein the presence of a mutation selected from, in one embodiment include mutations at codons stT45, sL 73, sL175, s1195, sTl18, sPl20, sP127, s1195, sTI14, S1195, sS204, s1208, sS210, sVl4, sGl30, sM133, sW172, sS204 or sS210 such as sT45K, sL]73L/F, sLI75F, sl195M and in another embodiment include and sTI18A, sPI20T, sP127A and sil95M, or yet another 10 embodiment include sTl 14P, sl195M, sS204N, s1208T, and sS2IOR, or still yet another embodiment include sVl4A, sG130R, sMl33T, sW172L, sS204G, sS2lOR or a combination thereof or an equivalent mutation, in even still another embodiment, rtN53K, rtN53K/N, rtY54D, rtLl80M, rtTl81A/V rtTl84S, rtM204V, and rtN236T, in another embodiment include rtYl24H, rtHl26R, rtTl28N, rtSl35C, rtL180M rtS202C rtM204V, 15 and rtH248N, or yet another embodiment include rtl53V, rtS54T, rtN122T, rtM145L, rtLl80M, rtM204V and rtM250L, or still yet another embodiment include rtN53D, rtS85A, rtSl 16P, rtDI34V, rtN139E/K, rtQl49K, rtAl81V, rtS2l9A, rtl233V, rtN236T, rtM250L or a combination thereof or an equivalent mutation, or combinations thereof or an equivalent one or more other mutation is indicative of a variant which exhibits a decreased 20 sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and LMV; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; 25 ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-H BV agents or combinations thereof. A further aspect of the present invention produces a method for determining whether an 30 -IBV strain exhibits reduced sensitivity to a nucleoside or nucleotide analog or other anti H-BV agents, said method comprising isolating DNA or corresponding mRNA from said C \NRPonlnh CC\AAR"u6931 II DOC-I/05/2012 -43 HBV and screening for a mutation in the nucleotide sequence encoding the DNA polymerase and/or a corresponding region of the S gene, wherein the presence of a mutation selected from, in one embodiment, mutations at codons stT45, sLl73, sL175, s1195, sTl18, sPl20, sP127, s1195, sT114, S1195, sS204, s1208, sS210, sVl4, sGl30, 5 sM133, sW172, sS204 or sS210 such as sT45K, sL173L/F, sL175F, slI95M and in another embodiment include and sTI 18A, sPl20T, sP127A and sIl195M, or yet another embodiment include sTl 14P, sl195M, sS204N, sl208T, and sS2IOR, or still yet another embodiment include sV14A, sG130R, sM133T, sW172L, sS204G, sS21OR or a combination thereof or an equivalent mutation, in even still another embodiment, rtN53K, 10 rtN53KIN, rtY54D, rtLl80M, rtTl8lA/V rtTl84S, rtM204V, and rtN236T, in another embodiment include rtYl24-1, rt-1126R, rtTl28N, rtSl35C, rtLl80M rtS202C rtM204V, and rtH248N, or yet another embodiment include rtl53V, rtS54T, rtN122T, rtMl45L, rtLl80M, rtM204V and rtM250L, or still yet another embodiment include rtN53D, rtS85A, rtSI16P, rtDl34V, rtNl39E/K, rtQl49K, rtAl81V, rtS219A, ril233V, rtN236T, rtM250L 15 or a combination thereof or an equivalent mutation, combinations thereof or an equivalent one or more other mutation is indicative of a variant which exhibits a decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and 20 LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. 25 The detection of IBV or its components in cells, cell lysates, cultured supernatant fluid and bodily fluid may be by any convenient means including any nucleic acid-based detection means, for example, by nucleic acid hybridization techniques or via one or more polymerase chain reactions (PCRs). The term "bodily fluid" includes any fluid derived 30 from the blood, lymph, tissue or organ systems including serum, whole blood, biopsy and biopsy fluid, organ explants and organ suspension such as liver suspensions. The invention C \NRPorbl\)CC\AAR\4306931_ I.DOC-4/052I012 - 44 further encompasses the use of different assay formats of said nucleic acid-based detection means, including restriction fragment length polymorphism (RFLP), amplified fragment length polymorphism (AFLP), single-strand chain polymorphism (SSCP), amplification and mismatch detection (AMD), interspersed repetitive sequence polymerase chain 5 reaction (IRS-PCR), inverse polymerase chain reaction (iPCR) and reverse transcription polymerase chain reaction (RT-PCR), amongst others. Other forms of detection include Northern blots, Southern blots, PCR sequencing, antibody procedures such as ELISA, Western blot and immunohistochemistry. A particularly useful assay includes the reagents and components required for immobilized oligonucleotide- or oligopeptide-mediated 10 detection systems. One particularly useful nucleic acid detection system is the reverse hybridization technique. In this technique, DNA from an HBV sample is amplified using a biotin or other ligand-labeled primer to generate a labeled amplificon. Oligonucleotides 15 immobilized to a solid support such as a nitrocellulose film are then used to capture amplified DNA by hybridization. Specific nucleic acid fragments are identified via biotin or the ligand. Generally, the labeled primer is specific for a particular nucleotide variation to be detected. Amplification occurs only if the variation to be detected is present. There are many forms of the reverse hybridization assay and all are encompassed by the present 20 invention. Another aspect contemplated by the present invention provides a method for detecting a variant HBV exhibiting an altered immunological profile said method comprising isolating an -BV from a subject exposed to a nucleoside or nucleotide analog selected from the 25 listed consisting of ADV, LMV, TFV, ETV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and LMV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV 30 and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and C:MRPortb\DCCAAR\41..IDOC-/)5/2012 -45 ETV and/or optionally other nucleoside or nucleotide analogs or other anti-I-IBV agents or combinations thereof, and then contacting said HBV with a panel of one or more antibodies to a surface antigen and screening for any change in binding affinity or binding spectrum. 5 In a related embodiment, the present invention contemplates a method for detecting a variant HBV exhibiting an altered immunological profile said method comprising isolating a serum sample from a subject exposed to a nucleoside or nucleotide analog selected from the listed consisting of ADV, LMV, TFV, ETV or FTC; ADV and LMV; ADV and TFV; 10 LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and LMV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV 15 and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-I-IBV agents or combinations thereof, and then contacting the serum with a panel of HBV surface antigens or antibody-binding fragments thereof and screening for any change in binding affinity or binding spectrum. 20 Detecting HBV replication in cell culture is particularly useful. This and other aspects of the present invention is particularly amenable to microarray analysis such as to identify oligonucleotides including sense and antisense molecules, 25 RNAi or siRNA molecules or DNA or RNA-binding molecules which down-regulate genomic sequences or transcripts of I-IBV. Microarray analysis may also be used to identify particular mutations in the HBV genome such as within the B113V DNA polymerase-coding region or the -IBsAg-coding region. 30 Another aspect of the present invention contemplates a method for detecting an agent which exhibits inhibitory activity to an HBV by: C:\NRPonbMDCC\AAR\4 B l_1 DOC-41S/2012 -46 generating a genetic construct comprising a replication competent-effective amount of the genome from the IBV contained in a plasmid vector and then transfecting said cells with said construct; 5 contacting the cells, before, during and/or after transfection, with the agent to be tested; culturing the cells for a time and under conditions sufficient for the HBV to 10 replicate, express genetic sequences and/or assemble and/or release virus or virus-like particles if resistant to said agents; and then subjecting the cells, cell lysates or culture supernatant fluid to viral- or viral-component-detection means to determine whether or not the virus has replicated, 15 expressed genetic material and/or assembled and/or been released in the presence of the agent. In a preferred embodiment, the plasmid vector may include genes encoding part or all of other viral vectors such as baculovirus or adenovirus (Ren and Nassal, 2001, supra) and 20 the method comprises: generating a genetic construct comprising a replication competent-effective amount of the genome from the H-BV contained in or fused to an amount of a baculovirus genome or adenovirus genome effective to infect cells and then infecting said cells with 25 said construct; contacting the cells, before, during and/or after infection, with the agent to be tested; C-\NRPorbl\DCC\A ARk 31. I DOC-4/212M2 - 47 culturing the cells for a time and under conditions sufficient for the -1BV to replicate, express genetic sequences and/or assemble and/or release virus or virus-like particles if resistant to said agent; and 5 then subjecting the cells, cell lysates or culture supernatant fluid to viral- or viral-component-detection means to determine whether or not the virus has replicated, expressed genetic material and/or assembled and/or been released in the presence of the agent. 10 In an alternative embodiment, the method comprises: generating a continuous cell line comprising an infectious copy of the genome of the HBV in a replication competent effective amount such that said infectious HBV genome is stably integrated into said continuous cell line such as but not limited to 2.2.15 15 or AD; contacting the cells with the agent to be tested; culturing the cells for a time and under conditions sufficient for the HBV to 20 replicate, express genetic sequences and/or assemble and/or release virus or virus-like particles if resistant to the agent; and then subjecting the cells, cell lysates or culture supernatant fluid to viral- or viral-component-detection means to determine whether or not the virus has replicated, 25 expressed genetic material and/or assembled and/or been released in the presence of the agent. The above-mentioned methods are particularly useful in identifying or developing agents against HBV variants such as those carrying mutations, in one embodiment, mutations at 30 codons rtN53, rtY54, rtLl80, rtTl81, rtT184, rtM204, rtN236, rtYl24, rtl-1126, rtTl28, rtS135, rtLl80, rtS202, rtM204, rt-1248, rt153, rtS54, rtN122, rtM145, rtLl80, rtM204, C \NRPotb DCC AAR\43911_ DOC4/152012 -48 rtM250, rtN53, rtS85, rtSl 16, rtD134, rtN139, rtQ149, rtAl8l, rtS219, rt!233, rtN236 or rtM250 such as rtN53K, rtN53K/N, rtY54D, rtL180M, rtTl81A/V rtTl84S, rtM204V. and rtN236T, in another embodiment include rtYl24-l, rt-1l26R, rtTl128N, rtSl35C, rtLl80M rtS202C rtM204V, and rt-1248N, or yet another embodiment include rtl53V, rtS54T, 5 rtN122T, rtM145L, rtLl80M, rtM204V and rtM250L, or still yet another embodiment include rtN53D, rtS85A, rtSll6P, rtD134V, rtN139E/K, rtQl49K, rtAl81V, rtS219A, rt1233V, rtN236T, rtM250L or a combination thereof or an equivalent mutation, or a combination thereof or an equivalent mutation; in a further embodiment, mutations at codons stT45, sL173, sL175, s1195, sTl18, sPl20, sPl27, s1195, sTl14, S1195, sS204, 10 s1208, sS210, sV14, sG130, sM133, sW172, sS204 or sS2l0 such as sT45K, sLI73L/F, sL175F, sl195M and in another embodiment include and sTl 18A, sPI20T, sPl27A and s1l95M, or yet another embodiment include sTl14P, sll95M, sS204N, sl208T, and sS210R, or still yet another embodiment include sVI4A, sG130R, sM133T, sWI72L, sS204G, sS21OR or a combination thereof or an equivalent mutation. 15 Accordingly, another aspect of the present invention contemplates a method for determining whether an IBV strain exhibits reduced sensitivity to a nucleoside or nucleotide analog or other potential anti--IBV agent, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the 20 nucleotide sequence of the envelope genes or DNA polymerase gene selected from, in one embodiment, in one embodiment, mutations at codons rtN53, rtY54, rtLl80, rtTl8l, rtT184, rtM204, rtN236, rtY124, rtl-1126, rtT128, rtS135, rtL180, rtS202, rtM204, rtl-1248, rt153, rtS54, rtN122, rtM145, rtLl80, rtM204, rtM250, rtN53, rtS85, rtSl16, rtDl34, rtN139, rtQl49, rtA181, rtS219, rt1233, rtN236 or rtM250 such as rtN53K, rtN53K/N, 25 rtY54D, rtLl80M, rtTl81A/V rtTl84S, rtM204V, and rtN236T, in another embodiment include rtY124H, rtl-1126R, rtTl28N, rtS135C, rtl,180M rtS202C rtM204V, and rtl-1248N, or yet another embodiment include rtI53V, rtS54T, rtN122', rtMl45L, rtL180M, rtM204V and rtM250L, or still yet another embodiment include rtN53D, rtS85A, rtSi 16P, rtDl34V., rtN139E/K, rtQl49K, rtA]81V, rtS219A, rtl233V, rtN236T, rtM250L, or a combination 30 thereof or an equivalent mutation, or a combination thereof or an equivalent mutation; in a further embodiment, mutations at codons stT45, sLl73, sL175, s1195, sTl 18, sPl20, C.\NRPonbI\DCC\AAR\41M'(" _1 DOC-4"512()12 - 49 sPl27, s195, sT 114, S1195, sS204, s1208, sS2l0, sV l4, sG130, sM133, sWl72, sS204 or sS210 such as sT45K, sLI73L/F, sL175F, sl195M and in another embodiment include and sTI18A, sPl20T, sP127A and sl195M, or yet another embodiment include sTl14P, sIl95M, sS204N, sl208T, and sS210R, or still yet another embodiment include sVI4A, 5 sG130R, sMI33T, sW172L, sS204G, sS2IOR or a combination thereof or an equivalent mutation and/or optionally other nucleoside or nucleotide analogs or other anti-I-IBV agents or combination thereof. The detection of amino acid variants of DNA polymerase is conveniently accomplished by 10 a range of amino acid detection techniques. Where an HBV variant comprises an amino acid change, then such an isolate is considered a putative HBV variant having an altered DNA polymerase activity. The present invention further contemplates agents which inhibit HBV variants resistant to 15 ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and 20 ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti--IBV agents or combinations thereof resistant HBV variants. Such agents are particularly useful if long term treatment by ADV, LMV, FTC, TFV and/or ETV and/or optionally other nucleoside or nucleotide analogs such as TFV is 25 contemplated by the clinician. The agents may be DNA or RNA or proteinaceous or non proteinaceous chemical molecules. Natural product screening such as from plants, coral and microorganisms is also contemplated as a useful potential source of masking agents as is the screening of combinatorial or chemical libraries. The agents may be in isolated form or in the form of a pharmaceutical composition or formulation and may be administered in 30 place of or sequentially or simultaneously with a nucleoside or nucleotide analog. Furthermore, rationale drug design is contemplated including solving the crystal or NMR C.\NRPonbl\DCC\A A R 110693_I DOC-48/5/2 12 - 50 structure of, for example, HBV DNA polymerase and designing agents which can bind to the enzyme's active site. This approach may also be adapted to other HBV components. Accordingly, another aspect of the present invention contemplates a method for detecting 5 an agent which exhibits inhibitory activity to an HBV which exhibits resistance or decreased sensitivity ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; T1V and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV 10 and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof and/or optionally other nucleoside or nucleotide analogs or other anti--1BV agents or 15 combination thereof, said method comprising: generating a genetic construct comprising a replication competent-effective amount of the genome from said HBV contained in a plasmid vector and then transfecting said cells with said construct; 20 contacting said cells, before, during and/or after transfection, with the agent to be tested; culturing said cells for a time and under conditions sufficient for the HBV to 25 replicate, express genetic sequences and/or assemble and/or release virus or virus-like particles if resistant to said agent; and subjecting the cells, cell lysates or culture pupernatant fluid to viral- or viral component-detection means to determine whether or not the virus has replicated, expressed 30 genetic material and/or assembled and/or been released in the presence of said agent.

C\NRPorbl\DCC1AAR\41106, 31_ .DOC-4/05/2012 -51 Still another aspect of the present invention provides a method for detecting an agent which exhibits inhibitory activity to an HBV which exhibits resistance or decreased sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and 5 TFV; ADV and LMV and TFV; or ADV and FTC and lFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other 10 nucleoside or nucleotide analogs or other anti--IBV agents or combinations thereof and/or optionally other nucleoside or nucleotide analogs or other anti-IBV agents or combination thereof, , said method comprising: generating a genetic construct comprising a replication competent-effective 15 amount of the genome from said HBV contained in or fused to an amount of a baculovirus genome effective to infect cells and then infecting said cells with said construct; contacting said cells, before, during and/or after infection, with the agent to be tested; 20 culturing said cells for a time and under conditions sufficient for the HBV to replicate, express genetic sequences and/or assemble and/or release virus or virus-like particles if resistant to said agent; and 25 subjecting the cells, cell lysates or culture supernatant fluid to viral- or viral component-detection means to determine whether or not the virus has replicated, expressed genetic material and/or assembled and/or been released in the presence of said agent. Preferably, the HBV genome is stably integrated into the cells' genome. 30 C.NR~orblJCC\AAR"'6"1J DOC-1d/212 - 52 Particularly useful cells are 2.2.15 cells (Price el al., Proc. Nail. Acad. Sci. USA 86(21). 8541-8544, 1989 or AD cells (also known as HepAD32 cells or -IepAD79 cells [Ying et al., 2000 Spra]. 5 Whilst the baculovirus vector is a particularly useful in the practice of the present invention, the subject invention extends to a range of other vectors such as but not limited to adenoviral vectors. The present invention further extends to cell lines (e.g. 2.2.15 or AD cells) carrying genetic 10 constructs comprising all or a portion of an HBV genome or a gene or part of a gene therefrom. The present invention also provides for the use of the subject -1BV variants to screen for anti-viral agents. These anti-viral agents inhibit the virus. The term "inhibit" includes 15 antagonizing or otherwise preventing infection, replication, assembly and/or release or any intermediate step. Preferred anti-viral agents include nucleoside or nucleotide analogs or anti-I-IBV agents, however, the present invention extends to non-nucleoside molecules. In addition, rational drug design is also contemplated to identify or generate chemical 20 molecules which either mimic a nucleoside or which interact with a particular nucleotide sequence or a particular nucleotide. Combinatorial chemistry and two hybrid screening are some of a number of techniques which can be employed to identify potential therapeutic or diagnostic agents. 25 ln one example, the crystal structure or the NMR structure of polymerase or the surface antigen is used to rationally design small chemical molecules likely to interact with key regions of the molecule required for function and/or antigenicity. Such agents may be useful as inhibitors of polymerase activity and/or may alter an epitope on the surface antigen. 30 C:\NKPOnbl\DC(AAR116111 1.DC 92112 - 53 Several models of the HBV polymerase have been prepared due to the similarity with reverse transcriptase from HIV (Das et al., J. Virol. 75(10): 4771-4779, 2001; Bartholomeusz et al., Intervirology 40(5-6): 337-342 1997; Allen et al., Hepatology 27(6): 1670-1677, 1998). The models of the HBV polymerase can be used for the rational drug 5 design of new agents effective against -IBV encoding the resistant mutations as well as wild type virus. The rational drug that is designed may be based on a modification of an existing antiviral agent such as the agent used in the selection of the HIBV encoding the mutations associated with resistance. Viruses or clones expressing -IBV genomic material encoding the mutations may also be used to screen for new antiviral agents. 10 In an alternative embodiment, the present invention also contemplates a method for detecting an agent which exhibits inhibitory activity to an HBV polymerase in an in vitro polymerase assay. The HBV polymerase activity can be examined using established assays (Gaillard el al., Antimicrob Agents Chemother. 46(4). 1005-1013, 2002; Xiong et al., 15 Hepatology 28(6): 1669-1673, 1998). As indicated above, microarray technology is also a useful means of identifying agents which are capable of interacting with defined -IBV internal or external components. For example, arrays of HBV DNA polymerase or peptide fragments thereof carrying different 20 amino acid variants may be used to screen for agents which are capable of binding or otherwise interacting with these molecules. This is a convenient way of determining the differential binding patterns of agents between -IBV variants. Arrays of antibodies may also be used to screen for altered -IBsAg molecules. Microarrays are also useful in proteomic analysis to identify molecules such as antibodies, interferons or cytokines which 25 have an ability to interact with an HBV component. Microarrays of DNA and RNA molecules may also be employed to identify sense and antisense molecules for genetic regions on the IBV genome or transcripts thereof. The above methods are particularly useful in identifying an inhibitor of an -IBV resistant 30 to or exhibiting reduced sensitivity to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; C:\NRPorblDCC\AAR\43,91I1 .DOC-405/2012 - 54 ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; [TV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and 5 TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combination thereof. The present invention extends, therefore, to compositions of the inhibitors. The inhibitors may also be in the form of antibodies or 10 genetic molecules such as ribozymes, antisense molecules and/or sense molecules for co suppression or the induction of RNAi or may be other nucleoside or nucleotide analogs or other anti--1BV agents or derivatives of known analogs. Reference to RNAi includes reference to short, interfering RNAs (siRNA) and all RNAi-type molecules may be DNA derived or synthetic. 15 The term "composition" includes a "pharmaceutical composition" or a formulation. The inhibitor is referred to below as an "active ingredient" or "active compound" and may be selected from the list of inhibitors given above. 20 The composition may include an antigenic component of the HBV, a defective IBV variant or an agent identified through natural product screening or rational drug design (including combinatorial chemistry). 25 Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is 30 contemplated. Supplementary active ingredients can also be incorporated into the compositions.

C \NRPonbl\DCC\AAR\40693 I1.OC-4/05/2f 12 - 55 The pharmaceutical composition may also comprise genetic molecules such as a vector capable of transfecting target cells where the vector carries a nucleic acid molecule capable of encoding an aspartyl protease inhibitor. The vector may, for example, be a viral vector. 5 Pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. 10 The carrier can be a solvent or dilution medium comprising, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for example, by the use of superfactants. The preventions of the action of microorganisms can be brought about by various anti-bacterial and anti-fungal agents, for example, 15 parabens, chlorobutanol, phenol, sorbic acid, thirmerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin. 20 Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with the active ingredient and optionally other active ingredients as required, followed by filtered sterilization or other appropriate means of sterilization. In the case of sterile powders for the preparation of sterile injectable 25 solutions, suitable methods of preparation include vacuum drying and the freeze-drying technique which yield a powder of active ingredient plus any additionally desired ingredient. When the active ingredient is suitably protected, it may be orally administered, for 30 example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets. For oral CVNRPortbl\DCC\AARmU3,11_ I DOC-4/M/E012 - 56 therapeutic administration, the active ingredient may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, 5 of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 tg and 200 mg of active compound. Alternative dosage amounts 10 include from about I pg to about 1000 mg and from about 10 ptg to about 500 ng. These dosages may be per individual or per kg body weight. Administration may be per hour, day, week, month or year. The tablets, troches, pills, capsules and the like may also contain the components as listed 15 hereafter. A binder such as gum, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen or cherry flavouring. When the dosage unit form is a capsule, it may contain, 20 in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavouring. Of course, any material used in 25 preparing any dosage unit form should be pharmaceutically pure and substantially non toxic in the amounts employed. In addition, the active compound(s) may be incorporated into sustained-release preparations and formulations. As stated above, the present invention further extends to an isolated HBsAg from the H-BV 30 variants herein described. More particularly, the present invention provides an -IBsAg or a recombinant form thereof or derivative or chemical equivalent thereof. The isolated C \NRPrtbl\DCC\AAR\4169M 1_I DOC-405/2012 - 57 surface component and, more particularly, isolated surface antigen or its recombinant, derivative or chemical equivalents are useful in the development of biological compositions such as vaccine formulations. 5 Yet another aspect of the present invention provides a composition comprising a variant IHBV resistant to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and 10 LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-IBV agents or combinations thereof and/or optionally other nucleoside or nucleotide analogs or other anti--1BV agents or an HBV 15 surface antigen from said variant HBV or a recombinant or derivative form thereof or its chemical equivalent and one or more pharmaceutically acceptable carriers and/or diluents. Such a composition may be regarded as a therapeutic composition and is useful in generating an immune response including a humoral response. Generally, the IHBV variants are "defective" and in themselves are unable to cause a sustained infection in a 20 subject. As indicated above, antibodies may be generated to the mutant H4BV agents and used for passive or direct vaccination against infection by these viruses. The antibodies may be generated in humans or non-human animals. In the case of the latter, the non-human 25 antibodies may need to be deimmunized or more specifically humanized prior to use. Deimmunized may include, for example, grafting complimentarity determining regions (CDRs) from the variable region of a murine or non-human animal anti-HBV antibody onto a human consensus fragment antibody binding (Fab) polypeptide. Alternatively, amino acids defining epitopes in the variable region of the antibody may be mutated so that 30 the epitopes are no longer recognized by the human MHC I complex.

C \NRPonbl\DCC\AARu3(W.31_I I DOC.4/15/2012 - 58 Insofar as ribozyme, antisense or co-suppression (RNAi) or siRNA or complexes thereof repression is concerned, this is conveniently aimed at post-transcription gene silencing. DNA or RNA may be administered or a complex comprising RNAi or a chemical analog thereof specific for HBV mRNA may be employed. 5 All such molecules may be incorporated into pharmaceutical compositions. In another embodiment, the present invention provides a biological composition comprising a variant HBV or an -BsAg or L, M or S proteins from said variant H1BV or a 10 recombinant or derivative form thereof or its chemical equivalent. Generally, if an H4BV is used, it is first attenuated. The biological composition according to this aspect of the present invention generally further comprises one or more pharmaceutically acceptable carriers and/or diluents. 15 The biological composition may comprise -IBsAg or like molecule from one HBV variant or the composition may be a cocktail of HbsAgs or L, M or S proteins or like molecules from a range of ADV- and/or LMV- and/or, FTC- and/or TFV-resistant IBV variants. Similar inclusions apply where the composition comprises an IBV. 20 The present invention is further directed to the use of defective HBV variants in the manufacture of therapeutic vaccines to vaccinate individuals against infection by -IBV strains having a particular nucleotide sequence or encoding a particular polymerase or surface antigen or L, M or S proteins. 25 Examples of suitable vaccine candidates are defective forms of HIBV variants comprising a mutation selected from, in one embodiment, in one embodiment, mutations at codons rtN53, rtY54, rtLl80, rtTl81, rtT184, rtM204, rtN236, rtYl24, rt-1126, rtTl28, rtS135, rtL180, rtS202, rtM204, rtH248, rt153, rtS54, rtN122, rtM145, rtLl80, rtM204, rtM250, 30 rtN53, rtS85, rtS 116, rtD134, rtN139, rtQ149, rtA181, rtS2l9, rt1233, rtN236 or rtM250 such as rtN53K, rtN53K/N, rtY54D, rtLl80M, rtTI81A/V rtTl84S, rtM204V, and C\NRPorbN)CC\AARW,1W " I IDOC-4/I0['12 - 59 rtN236T, in another embodiment include rtYl24H, rtH126R, rtT128N, rtSl35C, rtLl80M rtS202C rtM204V, and rtH248N, or yet another embodiment include rt153V, rtS54T, rtNl22T, rtM145L, rtLl80M, rtM204V and rtM250L, or still yet another embodiment include rtN53D, rtS85A, rtSl16P, rtD134V, rtN139E/K, rtQl49K, rtAl8lV, rtS219A, 5 rtl233V, rtN236T, rtM250L or a combination thereof or an equivalent mutation, or a combination thereof or an equivalent mutation; in a further embodiment, mutations at codons stT45, sL173, sL175, sl195, sTl18, sPl20, sPl27, sl195, sTI 14, S1195, sS204, s1208, sS210, sV14, sGl30, sM133, sW172, sS204 or sS210 such as sT45K, sLI73L/F, sLI75F, sl95M and in another embodiment include and sT I 18A, sPI20T, sPI27A and 10 sl195M, or yet another embodiment include sTIl14P, sI195M, sS204N, sl208T, and sS210R, or still yet another embodiment include sVI4A, sG13OR, sMI33T, sWI72L, sS204G, sS21OR or a combination thereof or an equivalent mutation. In one embodiment, for example, an -IBV variant may be identified having a particular 15 mutation in its polymerase conferring resistance or decreased sensitivity to a nucleoside or nucleotide analog. This variant may then be mutated to render it defective, i.e. attenuated or unable to cause infection. Such a defective, nucleoside or nucleotide analog-resistant virus may then be used as a therapeutic vaccine against virulent viruses having the same mutation in its polymerase. 20 The subject invention extends to kits for assays for variant I-IBV resistant to ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, 25 ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti-HBV agents or combinations thereof. Such kits may, for example, contain the 30 reagents from PCR or other nucleic acid hybridization technology or reagents for immunologically based detection techniques. A particularly useful assay includes the C:\NRPonblDCC\AAR\4W-1 -O.DOC-4/05/212 -60 reagents and components required for immobilized oligonucleotide- or oligopeptide mediated detection systems. Still another aspect of the present invention contemplates a method for determining the 5 potential for an -1BV to exhibit reduced sensitivity to ADV, LMV, 'FV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and 10 TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti HBV agents or combinations thereof and/or optionally other nucleoside or nucleotide analogs or other anti--IBV agents or combination thereof, said method comprising 15 isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in any one or more of domains F and G, and domains A through to E or a region proximal thereto of said DNA polymerase and associated with resistance or decreased sensitivity to ADV, LMV, TFV or FTC; ADV and 20 LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and 25 FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti 1BV agents or combinations thereof, wherein the presence of such a mutation is an indication of the likelihood of resistance to said ADV, LMV, TFV or FTC; ADV and LMV; ADV and TFV; LMV and TFV; FTC and ADV; FTC and TFV; FTC and LMV; 30 ETV and ADV; ETV and FTC; ETV and TFV; ADV and LMV and TFV; or ADV and FTC and TFV; TFV and FTC and LMV; ADV and LMV and ETV, ADV and ETV and C\NRPrbRDC"AAR\U1 1I _I DOC-4/05112W2 -61 TFV; ETV and LMV and TFV; ADV and LMV and FTC; ADV and FTC and LMV and TFV; ETV and FTC and LMV and TFV; ADV and ETV and LMV and TFV; ADV and FTC and ETV and TFV; ADV and FTC and LMV and ETV; or ADV and FTC and LMV and TFV and ETV and/or optionally other nucleoside or nucleotide analogs or other anti 5 HBV agents or combinations thereof. With the proviso that the HBV variant does not exhibit resistance to ETV alone or ETV or LMV alone. An assessment of a potential viral variant is important for selection of an appropriate therapeutic protocol. Such an assessment is suitably facilitated with the assistance of a 10 computer programmed with software, which inter alia adds input codes for at least two features associated with the viral variants to provide a value corresponding to the resistance or sensitivity of a viral variant to a particular chemical compound or immunological agent. The value can be selected from (a) the ability to exhibit resistance for reduced sensitivity to a particular compound or immunological agent; (b) an altered 15 DNA polymerase from wild-type HBV; (c) an altered surface antigen from wild-type IBV; or (d) morbidity or recovery potential of a patient. Thus, in accordance with the present invention, the values for such features are stored in a machine-readable storage medium, which is capable of processing the data to provide a value for a particular viral variant or a biological specimen comprising same. 20 Thus, in another aspect, the invention contemplates a computer program product for assessing the likely usefulness of a viral variant or biological sample comprising same for determining an appropriate therapeutic protocol in a subject (Figure 15), said product comprising: 25 (1) code that receives as input code for at least two features associated with said viral agents or biological sample comprising same, wherein said features are selected from: 30 (a) the ability to exhibit resistance for reduced sensitivity to a particular compound or immunological agent; C:\NRPonbDCCAAR\4W931_I DOC-105/2"12 -62 (b) an altered DNA polymerase from wild-type 1BV; (c) an altered surface antigen from wild-type HBV; or (d) morbidity or recovery potential of a patient; 5 (2) code that adds said input code to provide a sum corresponding to a value for said viral variants or biological samples; and (3) a computer readable medium that stores the codes. 10 In a related aspect, the invention extends to a computer for assessing the likely usefulness of a viral variant or biological sample comprising same in a subject, wherein said computer comprises: (1) a machine-readable data storage medium comprising a data storage 15 material encoded with machine-readable data, wherein said machine readable data comprise input codes for at least two features associated with said viral variant or biological sample; wherein said features are selected from: 20 (a) the ability to exhibit resistance for reduced sensitivity to a particular compound or immunological agent; (b) an altered DNA polymerase from wild-type 1-11V; (c) an altered surface antigen from wild-type HBV; or (d) morbidity or recovery potential of a patient; 25 (2) a working memory for storing instructions for processing said machine readable data; (3) a central-processing unit coupled to said working memory and to said 30 machine-readable data storage medium, for processing said machine C.\NRPonbl\DCC\AAR\43169|_l DOC-4/05/2112 - 63 readable data to provide a sum of said input code corresponding to a value for said compound(s); and (4) an output hardware coupled to said central processing unit, for 5 receiving said value. Any general or special purpose computer system is contemplated by the present invention and includes a processor in electrical communication with both a memory and at least one input/output device, such as a terminal. Figure 15 shows a generally suitable computer 10 system. Such a system may include, but is not limited, to personal computers, workstations or mainframes. The processor may be a general purpose processor or microprocessor or a specialized processor executing programs located in RAM memory. The programs may be placed in RAM from a storage device, such as a disk or pre-programmed ROM memory. The RAM memory in one embodiment is used both for data storage and program 15 execution. The computer system also embraces systems where the processor and memory reside in different physical entities but which are in electrical communication by means of a network. In an alternative embodiment, the program screens for a mutation selected from, in one 20 embodiment, in one embodiment, mutations at codons rtN53, rtY54, rtLl80, rtTl81, rtT184, rtM204, rtN236, rtYl24, rtl-1126, rtTl28, rtSl35, rtL180, rtS202, rtM204, rt-1248, rt153, rtS54, rtN122, rtMl45, rtLl80, rtM204, rtM250, rtN53, rtS85, rtSll6, rtDl34, rtN139, rtQl49, rtA181, rtS219, rt1233, rtN236 or rtM250 such as rtN53K, rtN53K/N, rtY54D, rtL180M, rtT181A/V rtT184S, rtM204V, and rtN236T, in another embodiment 25 include rtYl24-1, rtH126R, rtT128N, rtS135C, rtLl80M rtS202C rtM204V, and rtH248N, or yet another embodiment include rtl53V, rtS54T, rtN 122T, rtM 145L, rtL 1 80M, rtM204V and rtM250L , or still yet another embodiment include rtN53D, rtS85A, rtSI16P, rtD134V, rtN139E/K, rtQl49K, rtAl8]V, rtS219A, rt1233V, rtN236T, rtM250L or a combination thereof or an equivalent mutation or a combination thereof or an equivalent 30 mutation; in a further embodiment, mutations at codons stT45, sLl73, sLl75, s1195, sf r18, sP120, sPl27, s1195, sTI 14, S1195, sS204, s1208. sS210, sV14, sG130, sM l33.

C.NRPortbu)CC\AAR\43e31_1 DOC-1-5/2012 - 64 sW172, sS204 or sS210 such as sT45K, sL]73L/F, sLI75F, sIl195M and in another embodiment include and sTi18A, sPl20T, sPl27A and sl195M, or yet another embodiment include sTI 14P, sl195M, sS204N, sl208T, and sS21OR, or still yet another embodiment include sVl4A, sGI30R, sM133T, sWI72L, sS204G, sS21OR or a 5 combination thereof or an equivalent mutation. The present invention is further described by the following non-limiting Examples.

C\NRPonbl\DCC\AARk41M')l1 I0OC-4,(I5/21112 - 65 EXAMPLE I Overlapping genome of HB V The overlapping genome of HBV is represented in Figure 1. The gene encoding DNA 5 polymerase (P), overlaps the viral envelope genes, Pre-SI and Pre-S2, and partially overlaps the X and core (C) genes. The HBV envelope comprises small, middle and large proteins HBV surface antigens. The large protein component is referred to as the HBV surface antigen (-IBsAg) and is encoded by the S gene sequence. The Pre-Sl and Pre-S2 gene sequences encode the other envelope components. 10 EXAMPLE 2 Patients on ADV Treatment and Analysis of HBV DNA Patient A: During ADV treatment, unique -IBV mutations were detected by PCR 15 amplification sequencing using the methods describedin Example 4; (Table 4). There was an evolution in the quasspecies detected. The mutation profile initially selected on ADV (sample A) includes the unique mutations at rtN53K, rtY54D, rtL180M, rtTl84S, and rtM204V. A key unique mutation is rtTl84S. Subsequently, a different ADV resistance profile was detected in sample B rtN53K/N, rtL180M, rtTI81A/V, and rtN236T. Key 20 unique mutations are rtTl8]A/V, and rtN236T detected previously in ADV resistant patients (Table 4, Figures 3, 4, 5 6, 7 and 8). The changes in the HBsAg include sT45K, sLl75F, sl195M in sample A and in the subsequent sample B sT45K and sLI73L/F were detected. These unique changes were 25 compared to reference sequences from each of the eight genotypes A-H as well as a consensus sequence from pretreatment samples to determine unique changes Patient B: The IHBV mutations during ADV treatment are listed in Table 5 and Figures 9, 10, and 11. Key unique changes in the rt region of the HBV DNA polymerase 30 include rtS202C and rtl-1248N. Other changes in the H-BV polymerase while on ADV treatment include rtYl24-1, rtH126R, rtTl28N, rtS135C, rtLl80M and rtM204V. The C \NRPorblDCC\AARVA16931_1 DOC-4/I5/2012 - 66 changes in the HBsAg while on ADV treatment include sTl18A, sP12oT, sP127A and sl 195M. Patient C: The HBV mutations during ADV treatment are listed in Table 6 and 5 Figures 12, 13, and 14. The key unique change in the rt region of the 1-113V DNA polymerase included rtM250L. Other unique changes in the -IBV polymerase while on ADV treatment include rt153V, rtS54T. rtN122T, rtMl45L, rtLl8OM and rtM204V. The changes in the HBsAg while on ADV treatment include sTi 14P, sl195M, sS204N, sl208T, and sS21OR. 10 Patient D: This patient had initially selected ADV resistant mutations at rtN236T (Angus el al., Gastroenterology. 125(2):292-7. 2003). This patient was subsequently treated with ADV and LMV. There was a virological breakthrough during the combination antiviral therapy (refer to Figure 15 for a graphical representation of increase in -IBV DNA levels 15 (viral load) and ALT over time (days since the initiation of the first antiviral therapy). The IBV mutations during dual ADV and LMV treatment are listed in Table 7 and Figures 16, 17 and 18. By PCR amplification of the -IBV genome and direct sequencing the unique changes in the rt region of the HBV DNA polymerase include, rtD134V, rtNl39E/K, rt1233V, rtM250L. These occurred in association with the known ADV resistant mutations 20 at rtAl8IV and rtN236T. The key unique mutations include rtl233V and rtM250L. All unique changes in the HBV polymerase while on ADV And LMV treatment include rtN53D, rtSi 16P, rtD134V, rtN139E, rtA18IV, rtS219A, rtl233V, rtN236T, rtM250L. Clonal analysis was performed on a PCR amplified product encoding the polymerase genes, from HBV isolated at the time of virological breakthough (see Example 15). A 25 further key mutations were detected in this PCR amplified product at rtS85A other mutations at rtN139K/E and rtQl49K were also detected as minor species (Table 7 footnote). The changes in the HBsAg while on ADV and LMV treatment include sV14A, sGl30R, 30 sM 1 33T, sWI72L, sS204G, sS21OR.

C NRPor1hDCC\AR\430 IiI DOC-4/S/2012 - 67 EXAMPLE3 Detection of Viral Markers Hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), anti-IBe and 5 hepatitis B core antigen (HBcAg) specific IgG and IgM were measured using commercially available immunoassays (Abbott Laboratories, North Chicago, IL, USA). Hepatitis B viral DNA levels were measured using a capture hybridization assay according to the manufacturer's directions (Digene Hybrid Capture 11, Digene Diagnostics Inc., Beltsville, MD). The manufacturers stated cut-off for detecting HBV viremia in clinical 10 specimens was 0.7x]06 copies/ml or 2.5 pg/ml [Hl-lendricks el al., Am J Clin Pathol 104: 537-46, 1995]. -IBV DNA levels can also be quantitated using other commercial kits such as Cobas amplification HBV monitor kit (Roche). EXAMPLE 4 15 Sequencing of HB V DNA HBV DNA was extracted from 100 pl of serum as described previously by Aye el al., J. -lepatol. 26: 1148-1153, 1997. Oligonucleotides were synthesized by Geneworks, Adelaide, Australia. Amplification of the HBV polymerase gene or the entire HBV 20 genome has been described by Aye et al., 1997, supra and Ayres et al.. Methods Mol Med. 95:125-49, 2004. The specific amplified products were purified using PCR purification columns such as from MO BIO Laboratories Inc (La Jolla, CA) and directly sequenced using Big Dye 25 terminator Cycle sequencing Ready Reaction Kit (Perkin Elmer, Cetus Norwalk, CT). The PCR primers were used as sequencing primers, OSI 5'- GCC TCA TTT TGT GGG TCA CCA TA-3 (nt 1408-1430) ISEQ ID NO:l], TTA3 5'-AAA TTC GCA GTC CCC AAA 3'(nt2128-2145) [SEQ ID NO:2], JM 5'-TTG GGG TGG AGC CCT CAG GCT 3'(nt1676-1696) [SEQ ID NO:31, TTA4 5'-GAA AAT TGG TAA CAG CGG -3' (nit 2615 30 2632) [SEQ ID NO:4], OS2 5' TCT CTG ACA TAC TTT CCA AT 3' (nt 2798-2817) [SEQ ID NO:5], to sequence the internal regions of the PCR products.

C:\NRPonbLCC\AARW1I XM 91 /212 - 68 EXAMPLE 5 Adefovir Dipivoxil (AD) 5 ADV (formerly Bis-pom PMEA)) is a potent inhibitor of lBV replication. The structure of ADV is shown in Figure 2 and its synthesis is described by Benzaria el al., J Med Chem. 39: 4958-4965, 1996). EXAMPLE6 10 In vitro analysis of antiviral resistance The sensitivity/resistance profile of HBV mutants to adefovir, tenofovir and other antiviral agents was examined in vitro using recombinant -IBV/baculovirus. The procedure for analysing the resistance profile is outlined in the following Examples 7-14. 15 EXAMPLE 7 Cell culture Sf21 insect cells were maintained in supplemented Grace's insect medium further 20 supplemented with 10% v/v heat-inactivated fetal bovine serum (Gibco BRL, Gaithersburg, MD) in humidified incubator at 28 C with CO 2 . HepG2 cells were maintained in minimal essential medium supplemented with 10% v/v heat-inactivated fetal bovine serum (MEM-FBS). HepG2 cells were grown in humidified 37C incubators at 5% v/v CO 2 . 25 C-\RPonblDCC\AAR\4306931_I.DOC-4/05/012 - 69 EXAMPLE 8 Preparation of HB V/baculovirus transfer vector with specific point mutations The recombinant HIBV/baculovirus system used for antiviral testing has been previously 5 described (Delaney el al., Antimicrob Agents Chemother 45(6): 1705-1013, 2001). In brief, the recombinant transfer vector was created by excising a fragment containing the l.3x HBV genome construct and cloning it into the multiple cloning region of a baculovirus vector pBlueBac4.5 (Invitrogen, Carlsbad, CA). Point mutations were created by site directed mutagenesis using the commercial kits according to the manufacturers 10 specifications (QuikChange, Stratagene). The nucleotide sequence of the plasmid and the point mutations generated by site directed mutagenesis were confirmed by sequencing using the ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit according to the manufacturer's specifications (Perkin Elmer, Cetus Norwalk, CT). The panel of IBV mutants was generated from a wild type (WT) genotype D IBV isolate by site 15 directed mutagenesis. Mutants encoded either WT HIBV polymerase or polymerase with the amino acid substitutions listed in Table 8 in an -IBeAg negative (precore [PC] G1896A mutant) background. Other IBV mutants can be made and tested for antiviral sensitivity in a similar manner. 20 EXAMPLE9 Generation of recombinant baculoviruses containing the 1.3 HB V construct Purified recombinant transfer vector and linear AcMNPV baculovirus DNA were co transfected into Sf21 cells using the BacNBlue transfection kit from Invitrogen (Carlsbad, 25 CA); recombinant viruses were isolated by plaque assay according to the manufacturer's instructions. A series of recombinant viruses were amplified from isolated plaques by infecting 100-mm dishes of Sf21 cells. Viral DNA was extracted from amplified viruses using standard procedures. Purified viral DNA was digested with restriction enzymes and then fractionated by electrophoresis in a 1% v/v agarose gel. Southern blotting was 30 performed to determine which virus isolates contained the intact 1.3 HBV construct. A Boehringer Mannheim Random Prime DNA Labeling kit (Indianapolis, IN) was used to C NRPorbhIDCC\AAR\U 1 _1 DOC.4/I5/212 - 70 generate IP 3 2 ]-radiolabeled probes. A full-length double-stranded IBV genome was used as a template for all radiolabeled probes. Viral DNA sequence was confirmed by PCR amplification and sequencing of the polymerase catalytic region. 5 EXAMPLE 10 Preparative baculovirus amplification and purification Baculoviruses were amplified by infecting suspension cultures of Sf21 cells in log phase at a multiplicity of infection (moi) of 0.5 pfu/cell. Infections were allowed to proceed until a 10 majority of the cells in the flasks showed visible signs of infection (four to five days). Virions were concentrated from infected Sf2l medium by centrifugation at 80,000 x g and purified through a 20-60% w/v sucrose gradient. Purified virus was titrated in quadruplicate in Sf21 cells by end-point dilution. An aliquot of each high titer stock was used for DNA extraction. The polymerase gene was amplified and sequenced to confirm 15 the presence of the site-directed mutagenesis. EXAMPLE II Infection (ie., Transduction) of HepG2 cells with recombinant HB V expressing baculovirus with antiviral agents 20 HepG2 cells were seeded at approximately 20-40% confluency and then were grown for 16-24 hours before infection. On the day of infection, triplicate plates of cells were trypsinized, and viable cell number was determined with a hemocytometer using Trypan blue exclusion. Average cell counts were calculated and used to determine the volume of 25 high-titer viral stock necessary to infect cells at the indicated moi. lepG2 cells were washed one time with serum-free MEM to remove traces of serum. Baculovirus was diluted into MEM without serum to achieve the appropriate moi using volumes of 1.0, 0.5, and 0.25 ml to infect 100-mm, 60 mm, and 35-mm dishes, respectively. Baculovirus was adsorbed to HepG2 cells for one hour at 37*C with gentle rocking every 15 minutes to 30 ensure that the inoculum was evenly distributed. The inoculum was then aspirated and C \NRPoriblDCC\AARhaW l_ IDOC-t012112 - 71 lHepG2 cells were washed two times with phosphate-buffered saline and refed MEM-FBS with or without various concentrations of agents. Replicate HepG2 cell cultures were transduced with WT or mutant HBV by means of 5 baculovirus vectors, and then exposed continuously to different concentrations of each drug 7 days. For each assay, five different concentrations of each drug were tested in duplicate. Drug concentrations for nucleoside analogs (LMV, FTC, L-dT and ETV) were (in nM) 1, 10, 100, 1,000 and 10,000. For the nucleotide analogs (ADV and TFV) concentrations used were 100, 500, 1,000, 5000 and 10,000 nM. Duplicate untreated 10 cultures served as controls. After 7 days culture, DNA was extracted and analysed. EXAMPLE 12 Analysis of secreted HBV antigen 15 Detection of hepatitis Be antigen (-IBeAg) was performed by radioimmunoassay and microparticle enzyme immunoassay using kits purchased from Abbott Laboratories (Abbott Park, IL, USA). Medium from HepG2 cells was collected, centrifuged at 6,000 g to remove cellular debris, transferred to clean tubes, and stored at 20'C until analysis. H-lBeAg values are expressed as fold of positive control. Medium samples were diluted 20 appropriately so that radioimmunassay results were below positive control values for HiBeAg.

C:\NRParbl\DCC\A A R41093 1_-1 DOC-4/05/2012 - 72 EXAMPLE 13 Detection of intracellular replicative intermediates -IBV core particles were isolated from the cytoplasmic fraction of lHepG2 cells lysed in 5 0.5% w/v NP-40. Cytoplasmic extracts were adjusted to 10 mmol/l McCl2 and unprotected DNA was removed by an incubation to 500 g/ml Proteinase K for 1.5 hours at 37 0 C. HBV DNA in the samples was then extracted using commercial DNA extraction kits such as Qiagen (DNA extraction) or in-house methods using sequential phenol and chloroform extractions, and the nucleic acids were recovered by ethanol precipitation. 10 Nucleic acids were resuspended in 50 jl /1 TE (10 mmol/l Tris, I mmol/l ethylenediaminetetraacetic acid), normalized by OD260, and digested with 100 g/ml RNase (Boehringer Mannheim, Indianapolis, IN) for one hour at 37 'C before analysis by real-time PCR or electrophoresis and Southern blotting using a full length [ 32 P]-labelled IBV and autoradiographed with the aid of Bio-Rad phosphorimaging screens. Images 15 were recorded and analysed using a Bio-Rad Model FX Molecular Imager equipped with "Quantity One" software. The amount of HBV DNA in drug-treated cells was expressed as a fraction of the mean amount of HBV DNA in untreated controls, defined as 1.0 based on image densities. Pairs 20 of values from duplicates were averaged to give a single value for each of three independent assays, from which means and standard deviations were calculated. The resulting data were analysed using TableCurve2l), which generated dose-response plots from which EC50, EC90 and AUC (area under curve) were estimated.

C-\NRPonbl\DCC\AAR\43II601_l.DOC-4/15/21012 - 73 EXAMPLE 14 Antiviral testing performed with wild-type and HB V/baculovirus encoding Polymerase mutations 5 The effect of the antiviral agents on the panel of mutants is shown in Table 9. Antiviral testing shows that the mutations previously selected on ETV at codons 184 and 202 in association with the LMV resistant mutants also affect sensitivity to ADV and TDF. The 184 and 202 mutations were selected by patients on ADV treatment alone (see patients A, and B). HBV encoding other mutations will be tested using similar methodology. 10 EXAMPLE 15 Clonal Analysis of I-BV Polymerase Mutants Selected During Antiviral Therapy Clonal analysis was performed at the time of the virological breakthrough on LMV and 15 ADV therapy to determine if mutiple HBV mutations are on the same genome for patient D. The catalytic domains of the reverse transcriptase/polymerase were amplified separartely using primers OSI and OS2 (refer to Example 4) sequenced as previously described Ayres et al., 2004 in supra). The OS/OS2 PCR products obtained from these samples were cloned into PCRScript Amp SK+ (Stratagene) as per the manufacturers 20 instructions. PCR amplification was carried out directly from each clone and the ICR product was sequenced for each sample as above, using the OSI/OS2 PCR primers as sequencing primers. During failure of ADV monotherapy, the patient previously selected rtN236T and rtAl81T. At the time of dual ADV and LMV resistance the mutation profile detected by amplification of the entire genome and direct sequencing included rtN53D. 25 rtSl 16P, rtDl34V, rtNl39E, rtAl81V, rtl233V, rtN236T. rtM250L. The rtN236T and the rtAl81T were detected in 100% of clones. Two major clonal profiles were detected: rtN139E+ rtQl49K+ rtM250L +rtl233V in 55% of clones and rtS85A + rtN139K+ rtN238D in 45% of the clones, respectively. The key mutation at rtS85A and the mutations at rtNl39E/K and rtQl49K were not detected by direct sequencing in the initial 30 amplification of the -IBV genome and PCR sequencing but was detected by directed sequencing of the clones and also the PCR product used for clonal analysis.

C-\NRPonbl\DCC\AAR\3191 I DOC4115/2112 - 74 The rtM250L mutation could affect sensitivity to entecavir as previously another mutation at codon rt250 was selected during ETV treatment. The rt1233V is located in a similar position in a sequence alignment with the HIV reverse transcriptase to the HIV codon 215 (Batholomeusz et al., Antivir Ther. 9(2):149-6, 2004) The rtM2041/V +/- rtLl80M 5 LMV resistance mutations were not detected in the clonal analysis at the time of virological breakthrough on combination ADV and LMV therapy. Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood 10 that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

C\NRPobKlDCC\AAR\431 9lI DOC-4/05/2U12 - 75 TABLE 4 Patient A HBV Polymerase and envelope mutations detected during A DV therapy Treatment HBV RT Mutations -BsAg Mutations LMV rtM132L sT1891/T Pre ADV rtL/MI80M sL/Pl92L rtA/V200A sT195T/I M/1204M sW/L196L ADV rtN53K sT45K rtY54D sL175F rtLI80M sl195M rtTI84T/S rtA200A/V rtM204M/l/V ADV rtN53K sT45K (Sample A) rtY54D sLlI75F rtL180M sl195M rtTl84S rtM204V ADV rtN53K/N sT45K (Sample B) rtLl80M sL173L/F rtT 181 A/V rtN236T 5 C:\NRPorhDCC\AAR\43(()l3 1I DOC4/0)5f2012 - 76 TABLE 5 Patient B RT and Polymerase mutations detected during ADV therapy Treatment HBV RT Mutations HBsAg Mutations ADV rtYl24H sT118A rtH126R, sP120T rtT128N sP127A rtS135C, s1195M rtLI80M rtS202C, rtM204V rtH248N 5 TABLE 6 Patient C RT and Polymerase mutations detected during ADV therapy Treatment HBV RT Mutations -IBsAg Mutations ADV rtlI6T sTI14P rtI53V sl195M rtS54T sS204N rtNl22T sI208T rtM145L sS2IOR rtLI80M rtM204V rtM250L- C \NRPonI DCC\AAR\4T ,93 I _1 DOC-I/I5II12 - 77 TABLE7 Patient D R T and Polymerase mutations detected by direct PCR amplification sequencing during AD Vand LMV therapy* Treatment -IBV RT Mutations HBsAg Mutations ADV and LMV rtN53D, sL173F rtS 116P, sS204G, rtDI34V, sS21OR rtL180M, rtA18IV, rtN238D ADV AND LMV* rtN53D, sV14A, rtSI 16P, (1946 days since start rtD134V, sG130R, of initial therapy) rtN l 39E, sM 1 33T, rtA181V sWI72L, rtS219A ,rt1233V, sS204G, rtN236T, sS21OR rtM250L 5 * In the clonal analysis the key mutation at rtS85A, and other mutations at rtNI39K/E and rtQI49K were also detected as minor species.

CWRPon,DtfCCNAAR43O691 II-DOC4t'52I2 - 78 TABLE 8 Description of HB V Mutants Code for HBV Reverse transcriptase (ri) amnino acid residueC number mutants 169 173 180 184 202 204 250 WT I V L T S M M LI 80M double I V M TI S V M L I80M quad I V M G I V M V 173 Ltriple I L M 'US V M 5 TABLE 9 Antiviral Results Summary poifjrir.se Charipe Lh4V F7C AD). TF I. ETV' L-dT ,10fte (WTN EC50 1.0 1.0 1.0 1.0 1.0 1.0 EC0O 1 0 1.0 1,0 1'0 1.0 10D AUGC 110 1.0 1.3 1.0 1.0 1.0 MO~M dauble EC50 '4,OZA] 1, 370 2.' 2,.3 70'). 4.7 EG;-0 >4,.35 '-263 1 .1 16 -,-1 -.04a 4 AUG. 3,13.1 7614 A I.7 1.1 215; 13.7 ECr-O ,-4,OCO :-1,370 1.S e..9 366,7 31.5 EGO ,-4.35 -263 2.9 2 -12,04a -41 AUIC 603.4 464.4 1.3 4.2 242,7 21.1 1,73L 1 f]e EC50 >4,OCO >1,.370 0.z 4.270 .7 ECGO -435 *-263 0.9 2. 9 719.5 -41 AUG 625.3 1200.0 OA 2.3 C11.5 12.7 C:\NRPont\DCC\AA R\31- I DOC-4/05/21f12 - 79 BIBLIOGRAPHY Allen et al., Hepatology 27(6): 1670-1677, 1998 Angus et al., Gastroenterology. 125(2):292-7. 2003 Aye ei al., J. Hepatol. 26: 1148-1153, 1997 Ayres et al., Methods Mol Med. 2004;95:125-49. Bartholomeusz ei al., Intervirology 40(5-6): 337-342 1997 Batholomeusz et al., Antivir Ther. 9(2):149-62004 Benhamou et al., Lancet 358: 718-723, 2001 Benzaria et al., J Med Chem. 39: 4958-4965, 1996 Boyd et al., Antiviral Chem Chemother. 32: 358-363, 1987 Calio ei al., Antiviral Res. 23: 77-89, 1994 Das el al., J. Virol. 75(10): 4771-4779, 2001 (Delaney et al., Antimicrob Agents Chemother 45(6): 1705-1013, 2001). Dienstag et al., New England .J Med 333: 1657-1661, 1995 Frick el al., Antimicrob. Agents Chemother.37: 2285-2292, 1993 Gaillard et al., Antimicrob Agents Chemother. 46(4): 1005-101 3, 2002 Gilson et al., J Viral Hepat 6: 387-395, 1999 Heathcote el al., Hepatology 28: A620, 1998 Hendricks e al., Am J Clin Pathol 104: 537-46, 1995 C:\NRPonhI\CC\AAR\431x3.|_ .DOC-4/520112 -80 Kruger et al., Hepatology 22: 219A, 1994 Main et al., J. Viral Hepatitis 3: 211-215, 1996 Norder el al.,(J. Gen. Virol. 74: 341-1348, 1993 Perrillo et al., Hepatology 32: 129-134, 2000 Peters et al., Transplantation 68: 1912-1914, 1999 Price et al., Proc. Natl. Acad Sci. USA 86(21): 8541-8544, 1989 Ren and Nassal, J. Virol. 75(3): 1104-1116, 2001 Severini et al., Antimicrobial Agents Chemother. 39: 430-435, 1995 Stuyver et al., Hepatology 33: 751-757, 2001 Summers and Mason, Cell 29: 403-415, 1982 Suo el al., J Biol Chem. 273(42). 27250-27258. 1998 Vere lodge, Antiviral Chem Chemother 4: 67-84, 1993 Xiong et al., -lepatology. 28(6): 1669-73, 1998 Ying ei al., J Viral Hepa. 7(2): 161-165, 2000

Claims (5)

1. 2. The isolated HBV variant of Claim 1 wherein the HBV further exhibits reduced sensitivity to lamivudine (LMV).
2. 3. A method for determining the potential for an HBV to exhibit reduced sensitivity to ADV said method comprising isolating DNA or corresponding mRNA from the HBV and screening for one or more substitution mutations in the gene encoding a DNA polymerase at a codon selected from the list consisting of rtTl84S, rtS202C. rtM250L. rtAl8]V, rtl233V, rtN236T and rtM250L. wherein the presence of at least one of these mutations is indicative of an HBV with reduced sensitivity to ADV.
3. 4. The method of Claim 3 wherein the lBV further exhibits reduced sensitivity to LMV. 5 Use of a variant IBV of Claim 1 or 2 in the manufacture of a medicament for the treatment of H-BV infection in a subject.
4. 6. Use of a variant lBV of Claim I or 2 in the manufacture of a diagnostic assay to detect an HBV and/or with reduced sensitivity to ADV and/or LMV.
5. 7. An isolated HBV variant of Claim I or 2 or a method of Claims 3 or 4 or a use of Claim 5 or 6 substantially as herein described with reference to the Figures and/or Examples.